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ABSTRACT

DESIGN AND DEVELOPMENT OF OLIGONUCLEOTIDE MICROARRAYS
AND THEIR APPLICATION IN DIAGNOSTIC AND PROGNOSTIC
ESTIMATION OF HUMAN GLIOMAS

By G. Scott Taylor
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University. Virginia Commonwealth
University, 2005
Director: Kenneth J. Wynne
DNA microarrays represent an ultra-high throughput gene expression assay
employed to study the transcriptomic profiles of biological tissues. These devices are
increasingly being used to study many aspects of gene regulation, and there is growing
interest in the biotechnology and pharmaceutical industries for developing such devices
in efforts toward rational product/drug design. The DNA microarray also provides a
unique and objective means for diagnosis and prognosis of human diseases based on
patterns of gene expression. This is especially important in cancer research and the thrust
toward personalized medicine. This dissertation details the design and development of
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oligonucleotide microarrays and the design and execution of a gene expression study
conducted using human glioma specimines. Chapter 2 details the design and development
a ~10,000 gene human oligonucleotide microarray. This device consisted of a 21,168
features, each composed of a particular human gene-probe and was applied to the
challenge of diagnostic and prognostic estimation for human gliomas (chapter 3).
Gliomas are the most frequent and deadly neoplasms of the human brain characterized by
a high misdiagnosis rate and low survival. The study in chapter 3 demonstrated that the
specified design and development parameters were appropriate for conducting gene
expression analysis and that this platform can be used successfully to predict malignancy
grade and survival for glioma patients.

CHAPTER 1. MICROARRAY TECHNOLOGY AND CONTEMPORARY DATA
ANALYSIS

ABSTRACT

Gliomas are the most frequent and deadly neoplasms of the human brain.
Although most glioma specimines can be histopathologically classified with a high
degree of accuracy, atypical gliomas are often difficult to classify by histological features
and outcome prediction error prone. Indeed, within highly characteristic glioma
specimens, much variation has been observed with regard to invasiveness, response to
therapy, and ultimately prognosis. Recent advances in transcriptomic profiling have
raised the possibility that DNA based devices can be developed to greatly improve
diagnostic and prognostic information aiding the clinician in planning treatment and
helping tailor treatments based on molecular characteristics of individual tumors. DNA
microarrays represent the current state of the art with respect to high-throughput
transcriptomic profiling. This chapter details the most important elements of microarray
technology, glioma genetics, and introduces how our efforts at technology development
have addressed critical issues with regard to design, fabrication, and molecular insight.

1

2

1.0 INTRODUCTION
The DNA microarray has been in use as a research technology for about ten
years1. The initial platform consisted of poly-L-lysine coated standard glass microscope
slides with cloned DNA (cDNA) polymerase chain reaction (PCR) products immobilized
by ionic / electrostatic interaction with the surface. Microarray technology has evolved
and now exists in three common platforms; i) photolithographically fabricated arrays, ii)
the cDNA array and iii) the oligonucleotide array. DNA microarrays have further evolved
to contain internal calibration and control features in addition to genomic probes (e.g.,
DNA probes obtained from the genome of an organism). The advantage the DNA
microarray holds over older techniques is in throughput and the ability to assess
correlative information to identify coregulated-gene networks (i.e., networks of genes
whose regulation is dependent on the other network members). The potential of this
technology is that all of the genes in the genome of an organism can be arrayed and
immobilized on a consistent single substrate in specific locations on the micrometer
scale. This ultimately enables an instantaneous snapshot of the entire active
transcriptomic profile (i.e., the profile of messenger RNA (mRNA) transcripts present in
the cell) in any given cell population or tissue. The huge advantage in throughput allows
the investigation of not only gene-wise and sample-wise differences in expression
patterns, but also biological complexity.
Microarrays have had a tremendous impact on cancer research allowing
investigators to discern gene expression networks as revealed in comparative analyses of
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tumor and normal tissue extracts and as diagnostic tools that essentially function by
pattern recognition. It has been reported, for instance, that microarray data can be more
accurate in predicting survival than histopathological grading for ambiguous samples2.
Further, the concept that gene expression patterns can help define treatment options has
been established widely 2-7, particularly lung cancer 8, colon5, breast9-11, and leukemia7,12.
These advances provide impetus for the development of a new class of devices that
utilize an empirically defined, targeted suite of genes to improve diagnostic resolution
prognostic estimation, and maximize the effectiveness of treatment regimens.
A major challenge faced by contemporary medicine is diagnostic and prognostic
estimation for brain cancer. Malignant glial tumors of the central nervous system,
collectively referred to as gliomas, present one outstanding example of the need for
improvement in predicitive technologies to inform treatment. Glial tumors are the most
frequent and deadly human neoplasms of the brain and kill and estimated 13,000 -17,000
Americans per year13. Decades of research into the cellular and molecular biology of glial
tumors (astrocytomas (AA) glioblastoma multiform (GM) and oligodendriogliomas
(OL)), has revealed a more coherent picture of the biology of these deadly neoplasms.
This effort has been aided and enhanced by the application of DNA microarrays,
although patient survival has not improved in 25 years13. Nevertheless, such data has
already yielded valuable insights into options for patient therapy. For example, the
presence of DAP-3, a protein associated with cellular motility and radiation resistance4,
was reported as over expressed in the invasive rim of a characteristic glioma. This protein
notably belongs to an anti-apoptotic network, suggesting that therapies aimed at inducing
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apoptosis, such as the chemotherapeutic cis-platin, or radiation therapy (whole brain and
gamma knife), are unlikely to eliminate the disease4. Indeed, there is only marginal
survival benefit correlated with the application of current treatments including
chemotherapy, radiotherapy, and surgical debulking of the tumor14.
Currently, the two most important factors in brain tumor survival are age at
diagnosis and tumor type histology (grade of malignancy). It is commonly believed that
DNA based devices will be integral in improving patient care and treatment while
simultaneously contributing to the identification of genetic targets for novel therapeutics.
This chapter is devoted to presenting DNA microarray technology, experimental design,
data analysis, and glioma biology and contemporary microarray classification efforts.
1.1 DNA MICROARRAY TECHNOLOGY
1.1.1 Preliminaries
DNA microarrays (MA) have emerged as a powerful technology for capturing the
instantaneous profile of messenger RNA (mRNA) transcripts (transcriptome) within any
given cell population3,4,6,11,12,15-20. A DNA microarray is composed of hundreds to
thousands of individual genes (probes), immobilized in a grid of discrete spots. There are
three commonly used platforms for DNA microarrays; i) in-situ photolithographically
synthesized oligonucleotide microarrays (typified by Affymetrix and Protogene
microarrays), ii) spotted cDNA microarrays, and iii) spotted oligonucleotide (oligo)
microarrays21, the latter two platforms are produced by non-contact or contact deposition
of the nucleic acids.
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Post fabrication, neglecting experimental design, microarray experiments are
conducted in five basic process steps i) harvesting of messenger RNA (mRNA) from
biological cells or tissue, ii) enzymatic replication and fluorescent labeling of harvested
1

3
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Figure 1.1. Schematic of the microarray experimental process. 1. mRNA is harvested from
biological cells. 2. Harvested mRNA is reverse transcribed and labeled. 3. This product is
applied to the surface of the microarray for the hybridization reaction, 4. After hy

bridization

the microarray is scanned. 5. The scanned image is quantified and the data is analyzed.
(Figure from http://www.ambion.com/techlib/resources/microarray/basics1.html )

mRNA, iii) hybridization of labeled target cDNA to immobilized probe on the array, and
iv) scanning and v) data analysis. Each step in the process has an associated set of
variables, and removing and/or standardizing variables in a process step is highly
desirable as microarray data is strongly influenced by variation imposed by these
variables.
Microarrays have major application in cancer research but also in expression
analysis (drug discovery, development, toxicology), single nucleotide polymorphism
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analysis22, gene discovery21, diagnostics23-25, genetic sub-typing10,15,26,27. While this is not
an exhaustive list, it illustrates the range of biological questions being addressed through
microarray analysis.
Concomitant with development of microarray technology has been the
investigation into methods for experimental design (ED), normalization, analysis, and
mining the extremely large amounts of data generated. While there are many types of
analysis that can be performed on microarray data, and finding an appropriate analysis
protocol can be challenging, there are guidelines to consider that aid in establishing
effective analysis. For instance, the nature of the query relates to the ED, which in turn
influences statistical precision. A loop design28 may be more effective for a drug vs. cell
line interaction study since there are limited conditions and statistical precision is high for
measures of significance. On the other hand, a reference design28 may be more
appropriate for a classification study where there could be hundreds of biological and
technical replicates and clustering methods are used that would be convoluted by the
complexity of a loop design.
1.1.2 Microarray Design and Fabrication
Microarray design takes into consideration the types and placement of features
(DNA-probes) for such parameters as intensity calibration, normalization, grid alignment,
positive control for hybridization, uniformity of hybridization, fidelity of reverse
transcription, and replication. By definition an array of gene-probes (features) is a 2D
arrangement of rows and columns of spots. This array is further partitioned into subarrays (subgrids) as a consequence of the utilization of multiple spotting pins during
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fabrication. Subgrid rows and columns are often referred to as meta-rows and metacolumns. Control and calibration features are typically embedded within the array to
gauge assay preformance.
Intensity calibration and normalization was traditionally performed through the
inclusion of so-called housekeeping control genes, randomly dispersed, throughout the
array21,29, 30. However, this method had its drawbacks as the genes originally considered
to have stable expression were actually found to be quite variable. A somewhat more
sophisticated method was the use of an “invariant set”, a set of constantly expressed
genes that could be determined during a pre-analysis step31 Yang, et al., reported the
inclusion of a ‘microarray sample pool’ feature composed of each probe present on the
microarray and deposited in a dilution series, to provide normalization parameters for
non-specific hybridization32. During image quantification, it is useful to have “land
marks” placed on the microarray sub-grid corners, to aid in alignment of the
segmentation grid. Such features can be genes known to have high abundance, or spikedin control probes that bind to pre-manufactured, labeled, complimentary DNA spiked into
the hybridization solution. Features such as these are also useful as positive controls for
hybridization and uniformity of hybridization. They are typically represented by genes
from an organism other than the one for which the bulk of the probes interrogate. Probes
that are complimentary for the 3´ and 5´ ends of a gene can be used to test for fidelity of
the reverse transcription and RNA integrity, the idea being that if reverse transcription
was preformed efficiently and RNA integrity is acceptable, than the ratio of the intensity
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from these spots should be close to one. Finally, it is useful to replicate each gene-probe
on the microarray as this replication can improve sensitivity and statistical precision32,33.
Fabrication of spotted DNA microarrays in its most general form is the process of
spotting single stranded (ssDNA) or double stranded DNA (dsDNA) on to the surface of
a particular substrate. This substrate historically has been nitrocellulose, nylon, or borosilicate glass (microscope slide). The array is produced using high precision robotics to
iteratively aspirate and dispense DNA fragments onto the substrate in a 2D grid
arrangement. The spotting is done by simply dipping specialized stainless steel or silicon
pins into a solution containing the DNA then contacting the substrate, thereby ejecting a
tiny fraction of the aspirated DNA solution onto the surface of the substrate. Factors that
influence the performance of the microarray include surface chemistry, spotting
concentration, spotting buffer, type of printed DNA, type of printing pin, production
time, length of production time, ambient humidity, production batch, and the curing
process.
Custom spotted microarrays are typically produced using a surface modified
standard microscope slide. Naturally, there are several surface modifications for
microarrays which can be categorized with respect to their surface interaction with the
DNA as covalent, non-covalent, or hydrogel. Poly-L-lysine (PLL), γaminopropyltrimethoxysilane (APS), and amino dendrimers, are examples of surface
modifications that interact with DNA non-covalently (Figure 2.2). PLL was the first
surface modification used for microarrays34, and is still commonly used. Generally
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surfaces that present free amines interact with DNA non-covalently. These surfaces are
most useful when printing unmodified PCR products.
Epoxy-silane (3-glycidoxypropyltrimethoxysilane (GPS)) and aldehyde-silane
surfaces are used in conjunction with 5'-NH2-C6 terminated oligos. A covalent bond is
formed between the epoxide ring (or carboxylic acid) and the amine terminus of the
oligonucleotide probe (Figure 2.2). These surfaces do not require a blocking step prior to
hybridization with the sample and exhibit reduced background with respect to the amine
surface35. The reason for this, we suggest, is a propensity for labeled cDNA to interact
electrostatically with the amine surfaces, hence the perceived necessity for blocking.
Notwithstanding, pre-hybridization blocking on GPS compared to amine surfaces is
associated with lower background for the GPS surface (Chapter 2)
Spotting concentration for DNA microarrays has been studied in great detail. It
has been reported that concentrations greater than ~6-10 µM do not significantly improve
intensity35,36. Zammatteo, et at., reported a maximal density of the probe of 600 fmol/cm2
which was reached a printing concentration of 0.5 µM37. We demonstrated that
increasing the spotting concentration of oligonucleotides over four orders of magnitude
(0.0001µg/µl –1µg/µl) resulted in only a marginal increase in signal intensity regardless
of the surface chemistry35 (Chapter 2).
1.1.3 Experimental Design for Microarrays
1.1.3.1 General Design Considerations and Sample Size
The practice of ED is traditionally coupled with the specific aims of the study
while emphasizing the parsimonious use of resources. The specific objectives and study
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design largely determine the statistical methods that will be used. When the purpose of
the study is to determine which factor has the greatest influence on the response variable,
analsis of variance (ANOVA) is the appropriate analytical method which models the
response’s dependence on important explanatory factors 38. Experimental design is
naturally, constrained by the goal of the study, the number of sample classes, desired
statistical power, efficiency, sample availability, type and level of replication, and so on.
However, the goal of ED is to maximize the information generated given the practical
constraints. The EDs discussed in subsequent sections are limited to a two-dye sample
labeling system.
The basic question for which microarray technology was developed, is finding
differential gene expression patterns among interesting biological comparisons. This is
known as differential gene expression analysis (DGEA). Approaches to answering this
question depend on the goals of the study. Methods for statistical inference such as the
student's t-test, ANOVA, significance analysis of microarrays (SAM), and proportional
hazards (regression) all have been successfully employed for DGEA on a gene-wise
basis28 39-41. In addition, such algorithms can also be used for feature selection for class
prediction investigations or for pathway studies28 39-41.
There are several ED's that are particularly useful for microarray studies. For a
two-dye system, each spot on a MA can be considered an experimental unit with block
size = 2. In this situation experiments with more than two comparisons are by default an
incomplete block design, which may be balanced or unbalanced. Due to differences in
spot uniformity, probe concentration, and hybridization uniformity, the value of
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hybridizing two samples to an array, is that the spot performance is “controlled”for by the
relative comparison. Microarray experiments must be executed in such a way that all
comparisons of interest are estimable a concept that underlies the ED approach.
There is generally thought be a significant effect due to the labeling dye. Consider
a situation where there are only two samples, one sample is labeled with dye 1, and the
other with dye 2 and an MA is hybridized. A researcher might decide to control for the
dye effect by switching the labeling assignments and performing another hybridization.
This set up is known as a dye-swap design, Figure 1.2. This design is very efficient with
respect to the estimation of statistical parameters, however it becomes impractical when

S-1
D-1

S-2
D-1

S-2
D-2

S-1
D-2

Figure 1.2. Dye-swap design. Samples are denoted S, dyes are denoted D, each
rectangle is an array
there are more than two classes compared. Differential gene expression analysis is carried
out by combining the per sample gene-wise intensity measures and fitting a one-way
model such as in Eq.1.6.
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For larger numbers of sample classes, an alternative design is the loop design.
Here, each sample is labeled with each dye and are paired on arrays as depicted in Figure
1.3. This design is also more efficient than the reference design until sample types reach
about ten42. This design is useful when there is only one factor (main effect).
Investigations with greater numbers of factors (i.e.: two cell lines subjected to two
different drugs) require another approach to ED.
S-1
S-2

S-3

S-5

S-4

Figure 1.3. Loop design for microarrays. Each arrow represents a microarray, the
circular end denotes labeling with dye 1, and the pointed end represents labeling with
dye 2.
While a loop design may be more efficient and precise for differential gene
expression analysis (DGEA), it is impractical for large sample sets. If one of the arrays is
lost or performs poorly, the ability to perform comparsons breaks down. Further, if more
samples are necessary in future analysis, it is difficult or impossible to integrate them.
However, for small sample sets the, greater level of replication provides an advantage in
terms of resource commitment over a replicated reference design42,43.
The reference design, depicted in Figure 1.4 is performed by co-hybridizing a
reference sample to each array along with the sample of interest. Because the reference
sample is always labeled with the same dye, a dye-swap design is not necessary. In
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addition the design as the advantages that it is simple, easily extensible, and facilitates
down stream analysis such as clustering easier than a loop design. A disadvantage of this
design is that for small numbers of samples, it is not as efficient as the dye-swap or loop
design. This translated into reduced precision in estimating DGE.
The take home message of the above discussion is that because of the interplay
between ED and the analysis procedures, researchers should carefully consider the downstream implications of selecting a design and whether the resources will be available to
properly utilize the advantages of the selected design.
Sample size (or level of replication), as a function of desired statistical power for
microarray data, can be estimated a-priori from preliminary data. These quantities also
depend on the precision of model parameter estimates, which is in turn a function of
design efficiency. For instance, because a loop design is more efficient than a reference
design, the level of replication in a loop design may be lower to achieve the same level of
statistical power. Again, estimation of sample size should be considered in the context of
the aim of the study.
One simple method for estimating sample size was described by Simon44, et al.,
where statistical power, P = (1 - β), for a given value of β is indicated in Eq. 1.1,
n = 4(z α / 2 + z β ) / (δ / σ )
2

2

[1.1]

Here, n = number of samples, zα/2 = percentiles of standard normal distribution zβ =
percentiles of standard normal distribution , δ = effect size σ = within class standard
deviation, where σ is estimated from prior data. The values of α and β must be chosen
with regard to multiple testing considerations. This is the general rule for specifying the
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type I and II error rates for microarray data since there are so many individual tests being
carried out during the analysis (equal to the number of genes or features on the array).
Generally, researchers are more tolerant of a moderate value for β (0.05) than for α.
When the goal of the study is to develop prognostic models the following was
also method reported by Simon, et al., to estimate sample size,
D = (z α / 2 + z β ) / (τ ln δ )
2

2

[1.2]

Where τ is the standard deviation of the gene-wise log ratio or intensity over all samples,
δ denotes the hazard ratio related to a unit change in the log ratio44.
This model takes into account that survival data are usually continuous and right
censored, and that there are not discrete differences between sample types as in a cell line
study.
Finally, technical replication in the form of replicated spots on the array and
hybridization of the same sample on multiple arrays provides estimates for measurement
error. Biological replication provides information on the distribution of gene expression
values for a given gene among individuals in the population. Thus, the amount and type
of replication are dependent on the objectives of the study. If the study is of the response
of a cell line to a type of drug, then technical replication improves sensitivity. On the
other hand, a study of tumors aimed at novel class discovery relies heavily on estimating
the variability across as many individuals as possible. The following discussion addresses
the characteristics, merits and demerits of EDs for microarrays.
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1.1.3.2 The Reference Design
The simplest design choice is a direct comparison of two samples (e.g., tumor vs.
normal) on one microarray. Experiments where there are more than two comparisons are
most effectively understood as incomplete block designs where each array (or spot)
constitutes a block of size d where d = number of dyes. If there more than two sample

R

R

R

R

S1

S2

S3

S4

Figure 1.4. A schematic of a reference design. Each box represents an array and each
sample (Si) is compared to the same reference RNA.
varieties (V), then we cannot assay all Vs on a single array and varieties must be assayed
in an alternative way to make all relevant comparisons possible. Let Vi be the variety of
sample being hybridized, where i = 1… n and for each array two varieties are applied. In
a reference design Vi is co-hybridized with a standardized reference Vr, and for
differential expression between varieties we are, in general, testing Ho: V1= V 2= …= V n.
Note that the values of V are the measures of expression used to calculate significance
and are ratios: generally, V g = I1/I2, where I is the estimated fluorescence intensity at
wavelengths 1 and 2 respectively. Since each variety of interest is compared to the same
reference the distance between any two samples is the same, which makes model fitting
and subsequent analysis easy. This design also has an advantage when large numbers of
samples are to be analyzed, it is extensible, and samples can be collected in a somewhat

16
haphazard fashion. However, due to the large degrees of freedom cost associated with the
reference sample, it is less efficient and parameter estimates are less precise.
This design is perhaps the simplest to execute and has the advantage of being
extensible such that samples can be assayed somewhat haphazardly42,44. Downstream
analysis such as clustering is also easy because the distance between samples is always
the same45. One criticism of this approach is that dye effects are completely confounded
with sample effects due to the fact that the reference is always labeled with the same dye.
This precludes specifying the DG term in an ANOVA model. However, in practice this is
of no consequence since researchers are not usually interested in the reference channel,
which essentially serves to correct for differences in feature performance. Another
criticism is that the reference design is inefficient compared to other designs. For large
sample sizes the reference is perhaps the most parsimonious choice since loop and dyeswap designs become impractically complex in execution and analysis.
In summary, by far, the reference design is the most widely used design for twochannel microarray hybridizations due to its simplicity of execution and intuitive nature.
The statistical properties of the reference design are often overlooked by the researcher
and can remain an afterthought due to its robustness. The biggest pitfall in utilizing this
design is that it is inefficient and statistical inference can be imprecise for small effect
sizes. One way to insulate against this is to design the microarray itself with replicate
spots and include as many technical and biological replicates as possible.
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1.2 DATA ANALYSIS FOR DNA MICROARRAYS
When considering analysis, it is useful to group the workflow into three
categories: i) pre-treatment, ii) normalization, iii) down stream analysis (i.e.: gene
expression analysis, clustering, and so on). During pre-treatment, raw expression data are
typically subjected various operations such as background subtraction, Log2
transformation, intensity filtering or variance filtering. Normalization methods are meant
to remove systematic noise from the data and can be applied within an array or across
arrays and/or both. Down stream analysis seeks to extract the biologically relevant
information contained in microarray data. Process such as differential gene expression
analysis45-48, hierarchical clustering41,42 supervised learning7,26,39,49, are commonly
performed to test hypotheses, discover gene interactions50, discover novel tissue subtypes2, delineate sample groupings41, or predict class membership5,6,11,12,16,17,23,25,45,47,51.
Since we are primarily interested in predicting class membership (i.e., histopathological
class or survival) the following sections describe contemporary methods for DGEA and
class prediction problems.
1.2.1 Data Normalization
Data transformation is the first step in the analysis process, and is applied to
stabilize variance or rescale and remove distributional artifacts caused by systematic
noise21,36. Data pre-treated in this way are then normalization by means of a number of
algorithms, the choice is left to the discretion of the researcher. A common postnormalization step is filtering, which can be done by intensity, variance, coefficient of
variation, or some other statistic. Control features (spots) embedded in the array can
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enable subsequent normalization and calibration. Common applications for within array
and between array normalization include total-intensity, invariant set, mean or median
centering, ANOVA, to standard deviation regularization, and scatter plot smoothers
(LOWESS)21,28,32,45,52.
Normalization of microarray data has been the subject of a growing body of
literature; as with other data treatments related to microarrays, there is little consensus,
and the community seems to be taking a situation specific approach. Nevertheless, certain
trends have become established. For instance, most available MA analysis software has
an implementation of LOWESS normalization (Biodiscovery, GeneSpring, TMeV) and
many MA studies report using this normalization during the analysis26,32,53,54,55. Further,
total-intensity normalization has been criticized due to its potential for over
smoothing32,56, and normalization to so-called ‘housekeeping genes’ has been similarly
debunked29.
The LOWESS algorithm is probably the most widely used normalization and is
essentially a scatter plot smoother developed for other applications57. It implicitly
assumes that 95% of genes have no expression change. In practice, the rule of thumb is
~70%. This algorithm fits a locally weighted polynomial to a neighborhood of points,
determines the weighted least squares fit on intensity measurement, ssg and computes a
fitted value ŝo = w(xo). The probe intensities are then adjusted by xnorm = 2A+ŝ/2. This
algorithm proceeds through the following steps, i) on an MA plot, otherwise known as
the ratio vs. intensity plot, transform the data such that A = ½ Log2(x*y) and M =
Log2(x/y) where x denotes the cy5 intensity of gene (g) and y denotes the cy3 intensity
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value of gene g, ii) take a point (xo) and find m nearest neighbors according to a specified
observational space f, typically f ≈ 0.4. iii) Compute the Euclidean distance from xo, |xi –
xo|, iv) compute the largest distance between xo and another point in the neighborhood,
∆(xo) = max(|xi – xo|). v) Assign weights to each point in N(xo) using the tricube weight
function:
⎧⎪(1 − u 3 ) 3 ,0 ≤ u ≤ 1
(|xi – xo|/ ∆(xo) = u , and w(u ) = ⎨
, otherwise
⎪⎩0

[1.3]

which basically assigns a smaller weight to points further from xo. vi) Calculate the
weighted least squares fit on ysg on the neighborhood N(xo), and take the fitted value
using w(u) as the weights. vii) Repeat this procedure for each xsg and adjust the probe
intensities by xnorm = 2A+ŝ/2.
This type of normalization has been shown to improve gene expression
measurements in self vs. self hybridizations for custom spotted microarray analysis32, and
can be applied with respect print-tip to take into account variations produced by the
individual printing pins. LOWESS normalization has the overall effect of re-centering the
distribution of gene expression values around zero on the y-axis of an MA plot and the
lower the value of f, the more aggressive the smoothing becomes.
Normalization can be accomplished implicitly in an ANOVA setting by fitting a
model such as Eq. 1.4 to the data.
yakghv =µ+Aa+Dk+Gg+ADak+VGig+DGkg+AGag+Sh(a)+ εakghv

[1.4]

20
where a for m arrays, k for o dyes, g for p genes, h for q spots, i for v
treatments/classes/groups.
Fitting this model to the data has the effect of partitioning the measured intensity
yakghv into various sums of squares and removing their quantities from the error term, thus
making the F-ratio larger (and more significant). Here µ is the overall mean of all
expression values for all arrays, A is the effect of array (a), D is the effect of dye (k), G
is the effect of gene (g), V is the effect of variety (i), and S is the effect of spot (h).
Combinations of terms, i.e.: ADak, denotes the interaction of the ath array with the kth dye.
This approach was initially described for microarrays by Kerr et al., and
Wolfinger, et al., and was demonstrated to produce a robust normalization that takes into
account array and dye effects and any other source of systematic noise that can be

Figure 1.5. Box plots before and after print tip LOWESS normalization. A. Before
LOWESS. B. After LOWESS.
encoded into the model. Examples include day of the week, experimenter, print tip, and
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so on28,43. In practice, approach is taken in the context of statistical inference and
normalized data from the model fitting step is not typically available for other analyses
due to its limited software implementations.

Figure 1.6. The effect of ANOVA normalization. Ratio vs. intensity plots displaying
the intensity values for a microarray before (left panel) and after (right panel) ANOVA
normalization.

1.2.2 Differential Expression Analysis (Feature Selection)
Often, the initial question of microarray data is which genes are differentially
expressed. Such DGEA is carried out by tests of inference including t-tests, ANOVA,
significance analysis of microarrays (SAM)39, Mann-Whitney U test, and Wilcoxon’s
matched pairs signed rank sum test28,43,46,47. Other than DGE, microarray data can be used
to study genetic regulation, discover gene function, and classify tissue samples.
For class comparisons, we are interested in whether the mean gene expression for
a given gene is significantly different between populations. The student’s t-test is used for
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two class comparisons. It can also be used to test against a constant such as two fold
expression. The test statistic assuming equal variance in the two groups is,

t=

y1 − y 2
s12 s 22
−
n1 n1

[1.5]

where t ~ t(df), yi is the mean for all y i= 1-2 and si is the sample standard deviation for
each i. Here we are testing the null hypothesis H0: µ1 = µ2 vs. the alternative H1: µ1 ≠ µ2.
For microarray data, the underlying distribution of gene expression values is often not
normal, hence, the reference distribution is commonly estimated through permutation of
the sample-wise gene expression values.
When there are more than two classes to be compared ANOVA can be used to
test significance of DGE. The most commonly implemented ANOVA model in
microarray analysis software is,
yig = µ + τig+ εig

[1.6]

which is a fixed effects gene-wise one-way model. The model assumes the ε ~ N(0, σ2)
and are independent, τ and ε are also independent, where i = 1, 2,…,t, indicates the level
of τ, and g indicates the gene. More complicated models such as [1.4] have been
employed that seek to model the known sources of variation.
Here the model parameters are estimated using the method of least squares58.
Briefly, the quantity to be minimized by least squares estimation is,
Q = ΣΣ(yig – µ − τ ig )2 [1.7]
The total variation associated with the data is given by the total sums of squares,
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SSY = ΣΣ( yig – y..)2

[1.8]

which can be further partitioned into sum of squares treatments (SST) [1.8] and sum of
squares error (SSE) [1.9]
SSY = SST +SSE

[1.9]

SST = ΣΣ( yi. – y..)2

[1.10]

SSE = ΣΣ( yig – yi.)2

[1.11]

The test of significance is the F-statistic, which is given by
F̂ = (SST/dfT)/(SSE/dfE)

[1.12]

that is, the ratio of the mean squares treatment, divided by mean squares error. A mean
squares quantity is simply the SS divided by its degrees of freedom. Here F̂ ~ F i-1, E-1.
With model [1.4] we are testing the null hypothesis: H0: All τi = 0 vs. HA: some (at least
two) of τi ≠ 0. Finally, the calculated F-statistic can be referenced to the F distribution or,
as with the t-test, to a distribution estimated by random permutations of the data28,38,43,58.
Multifactor ANOVA can be preformed as described in28,43,54 utilizing the
MAANOVA software by Wu, et al.. This R package provides an environment to
construct fixed effects or mixed models. Tests of significance are carried out by
computing F-ratios on model fitted residuals. Significance is assessed relative to an
estimated distribution based on sample or residual shuffling54. For a reference design
experiment, a model such as Eq. 1.13 would be appropriate to test for an effect due to the
variety (i) of sample (i.e., testing the hypothesis that at least two of the sample groups
will have significant differences in mean gene expression levels). This model, Eq. 1.13,
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estimates significance by taking into account systematic sources of noise due to the array,
dye, spot, and so on.

• Red indicates
indicates selected by
the F2 test

- LOG 10
tabulated p value
for the F1 test

Threshold for F3
test

Root mean square of the
relative expression values

Significance
threshold of
the F1 test

Figure 1.7. Volcano plot of the results of an F-Test. Significantly differentially
expressed genes are located in the upper right hand corner. Graphical features are noted
on the Figure.

Ho: yakghj =µ+Aa+Dk+Gg+ADak+VGig+DGkg+AGag+Sh(a)+Vi+εakghj

[1.13]

Here, µ is the mean of all spots on all arrays, A is the effect of array a, D is the
effect of dye k, G is the effect of gene g, AD is the array times dye interaction, VG is the
variety times gene interaction, DG is the dye times gene interaction, AG is the array
times gene interaction, S is the effect of spot h, and Vi is the ith variety
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(treatment/class/group). The genes declared as significantly differentially expressed via
F-tests of model comparisons are displayed in volcano plots (Figure 1.7). Significance is
assessed by computing three F-tests developed specifically for microarray data54.
Perhaps the most versatile test of significance for microarray data is the so-called
SAM39. This method can be employed for testing two classes, testing against a constant,
testing for differences among multiple classes, or censored survival45. This method
computes a value for d(g), which in the case of dichotomous inquiries, is a relative
distance, but can be replace by other functions such as the Cox proportional hazards
function Eq. 3.9 for survival analysis or for changes in expression between three or more
classes, d(g) can be defined in term of Fishers linear discriminant39.

d (g) =
s( g ) = a

{∑

m

x I ( g ) − xu ( g )
s( g ) + s0

[1.14]

[ x m ( g ) − x I ( g )] 2 + ∑n [ x n ( g ) − xυ ( g )] 2

}

[1.15]

Where x I (g) and xu ( g ) are the average levels of gene (g) expression in states I and U
respectively, s(g) is the standard deviation of the repeated expression measurements, Σm
and Σn are summations of the expression measurements in states I and U respectively, a =
(1/m+n)/(m+n-2), and m and n are the numbers of measurements in states I and U.
The t-test or pair-wise SAM were used for binary class comparisons, ANOVA
and multifactor SAM were used for multiple class comparisons and SAM censored
survival was used for survival analysis.
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1.2.3 Class Prediction using Microarray Data
Many class prediction scenarios have been considered using microarray
data2,7,26,41,45,49,50,59-67 and essentially fall into the machine learning class of algorithms. A
learning method is supervised if information regarding class labels or sample
characteristics is supplied to the algorithm. Examples of these included k-nearest
neighbors (k-NN), support vector machines (SVM), and Fisher’s discriminant analysis. It
is often necessary to remove genes from the data that have low situational relevance. In
such cases, differential gene expression analysis such as ANOVA, weighted voting, or
proportional hazards regression, can be used to select features (genes) that are most
relavent8,45,46,68, while other methods have been developed that effectively mine all of the
data for strong predictors of relevant biological information67. Alternatively,
unsupervised methods seek to find patterns in data without prior classification
information. These methods include hierarchical clustering, terrain maps, principle
components analysis (PCA), and the strong feature selection method by Kim et al.,67.
Consider a gene expression data set containing g genes and n mRNA samples
summarized as an n x p matrix X, where xsg ∈ X denotes the expression level of gene g in
mRNA sample s. For each mRNA sample for which the class membership is known the
data consists of the gene expression profile xs = (xs1,…,xsg) and a class label yl where l= 1
to the number of tumor classes k. A class prediction algorithm ψ seeks to partition the
space X in to k discrete subsets, Z1,…,Zk, such that for a sample with expression profile x
= (x1,…, xg) ∈ Zk , k is the predicted class47,67,69. We ultimately seek a classifier that is

consistent, meaning that the expectation of the cost of estimation, E(∆s) → 0 as s→ ∞,
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where ∆s= εs - εz, that is, the error of the classifier εs of ψs minus the Bayes error (εz ) for

s samples70. In other words, we would like the classifier to be achieve low error for the
entire real population given the limited training data.
When sufficient data is available, prediction parameters may be specified from a
training set (T) that contains known class distinctions such that T = {(x1,y1),…,(xs, ys)}.
The prediction parameters (i.e.: weight, distance, similarity) can then be applied to a
unknown set L such that L = {x1,…,xs} to predict the class (yk) of the observation xg in L
set47.
When yk is known, the prediction and true classes can be compared to estimate the
error rate of the predictor47 by methods such as leave-one-out cross validation (LOOCV)
or adding random error67. Here, the classifier is run on the data, but with one sample left
out, the classification rule is calculated for the remaining samples and is used to predict
the class of the omitted sample. Each sample xs is, in turn, left out and cross-validated.
The resulting classification for each member in the training set is then compared to the
true classification and an error rate is determined. This method works well for large
sample sizes and is unbiased, but can be over optimistic when samples are limited due to
increased error variance67.
Algorithms such as the signal-to-noise ratio (S2N)2,7, the independently consistent
expression discriminator (ICED)49, k-NN2,47, SVM49, gene shaving (GSH)50, and strong
feature set determination (SFSD)67,71 have been used successfully in class prediction via
gene expression. In the context of brain tumor research, k-NN and SFSD have been
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applied to find a limited panel of genes capable of reclassifying histologically ambiguous
tumors or distinguishing binary grade comparisons respectively7,67.
One of the first published algorithms specifically developed for prediction using
gene expression data was the S2N2,7. The ICED, inspired by the S2N, was demonstrated
to be more accurate in finding a dichotomous classification rule compared to analysis by
SVM and k-NN4. Both the S2N and ICED, however, have the disadvantage of being
binary classifiers. The other predictors introduced above (k-NN, SVM, GSH, SFSD), can
be used to address classification problems where there are greater than two classes
although our current implementation of SVM and GSH are for binary classifications.
Perhaps the most rigorous reported method was SFSD, an algorithm that finds feature
sets by first increasing the variance of the expression measures then uses a heuristic
guided random walk search algorithm to identify gene sets (three at most) that achieve a
low error rate67. Because microarray data contains large numbers of features combined
with multiple samples and sample classes, finding all optimal feature sets is
computationally intractable. Thus, researchers must rely on sub-optimal feature sets,
which may nevertheless perform very well by achieving an appreciably low error rate
while keeping in mind Occam’s razor; it is preferable to utilize a simple function that
explains most of the data than a complex one69.
A caveat to class prediction based on histological stage is that classification of the
samples used to train the model is subject the same histological classification error
present during the original classification. Samples that are, as such, incorrectly classified
are used to construct the classification parameters of the predictor, leading to bias. A way
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to circumvent this pitfall is to reclassify the samples into some other meaningful way,
such as by patient survival8 or in the case of GSH, set constraints that include class
relevant information50. Despite the challenges, gene expression profiles undoubtedly
contain information that can be used to construct prognostic estimates, and eventually
may supplant histological classification as the standard for diagnostics.
The following sections detail some common analysis and prediction techniques
employed in the microarray field. In the case of S2N, gene shaving, SVM, and SFSD,
feature sets are selected explicitly during the first stages of computation. For classifiers
such as k-NN, feature sets are usually chosen by some ‘outside’ algorithm such as
ANOVA or proportional hazards regression.
1.2.3.1 Signal-to-Noise Ratio
One of the earliest and most cited reports attempting to identify genes most that
are good predictors of class membership is the weighted voting algorithm developed by
Golub et al., known subsequently as the S2N7. This algorithm was initially shown to

Pg = [µ1 ( x g ) − µ 2 ( x g )] /[σ1 ( x g ) + σ 2 ( x g )] [1.16]

predict class membership between two types of leukemia. Their measure of “correlation”
Eq. 1.16 is a minor variant of a special case of sample maximum likelihood discrimination
rule
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C ( x) = arg min l

( x s − µ ls ) 2
∑ σ2
s =1− n
s

[1.17]

which has also been referred to as the diagonal linear discriminant analysis rule47
Eq. 1.17. This rule is evoked in when the class densities have the same diagonal
covariance matrix ∆ = diag(σ21,...,σ2n). For classes k = 2, the sample maximum likelihood
rule classifies an observation x = (x1,…,xl) as 1 iff
( x 1g − x 2 g ) 2 ⎛
(x + x 2g )
⎜ x g − 1g
∑
2
⎜
2
σˆ g
g =1−l
⎝

⎞
⎟≥0
⎟
⎠

[1.18]

which can be rewritten as Σgvg, where vg = ag(xg – bg), ag = ( x1g − x 2 g ) 2 / σˆ 2g . Here ag is
almost the same function used by Golub, et al., Eq. 1.16 except that the denominator is
the sum of the standard deviation of gene g instead of the variance47.
The correlation metric Pg= ag is used to weight the vote (v) function Eq. 1.18
which is the weighted vote for gene g. Further, Σ|v+j| = Vclass 1, and Σ|v-j|= Vclass 2, such that
the prediction strength for a sample under test is given as PS = Vclass1- Vclass2 / (Vclass1+
Vclass2). Significance was estimated by comparing the predicted classes to predictions
made by random permutations of the sample labels.
The S2N algorithm was initially applied to a leukemia data set that consisted of
72 total leukemia samples, some ALL and others AML. After training the algorithm with
38 samples, class membership was predicted among the remaining 34 samples. The
authors reported greater than 85% accuracy in predictions with various numbers of the
highest weighted genes7.
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1.2.3.2 ICED Analysis
Bijlani, et al., have recently (2003) developed an algorithm for distinguishing two
classes of samples and a finding a minimum number of predictor genes49. The algorithm:
Independently Consistent Expression Discriminator (ICED), is loosely based on a
measure of correlation (Pearson’s) followed by calculation and ranking of weighted
votes. It is inspired by the S2N ratio of Golub, et al., but was demonstrated to perform
better in terms of accuracy of prediction for the leukemia data set. ICED also allows for
the possibility of variable gene expression for a gene in one class but constant expression
of the same gene in the other class, while the S2N ratio would not likely vote such as
gene as a good discriminator. The equations for the algorithm are listed below Eqs. 1.191.23. Here the subscripts m,n denote the number of samples in each class, g denotes gene
(g), and g* indicates gene (g) in unknown sample g*.
ICED can be summarized in four steps to train the algorithm and three steps to
validate the predictors. The four training steps are: i) format data, ii) normalize (mean
centering), iii) rank each gene by weight statistic Eqs. 1.19, 1.20,

W1 g

W2 g

1
∑ | x2, g − µ1,m ( g ) |
m i =1− m
[1.19]
=
σ1,n ( g )

1
∑ | x1g − µ 2,m ( g ) |
n g =1− n
=
[1.20]
σ 2,m ( g )

to indicate its usefulness as a predictor, where m is the number of samples in class 1, n is
the number of samples in class 2, for gene g, iv) find optimal voters. Prediction consists

32
of i) format unknown sample data, ii) classify unknown samples using calculated votes
Eqs. 1.21, 1.22,
V1 g = W2 g • g * − µ 2TR , m ( g )

[1.21]

V2 g = W1 g • g * − µ 1TR ,n ( g )

[1.22]

and iii) assign class membership. The strength of prediction is given by Eq 1.23,
q•
P( g ) =

∑ V (g

g

)− p•

∑ V (g

g

)+ p•

g =1− p

q•

g =1− p

1

1

∑V

2

(g g i )

∑V

2

(g g i )

g =1− q

g =1− q

[1.23]

which falls in the interval [-1,1]. Large values of P(g) indicate greater prediction strength.
It is easily seen from inspection of Eqs. 1.21, 1.22 that the weight of a gene in
class-one is generated with respect to the standard deviation of the same gene in classtwo. The authors suggest that the voting equations are the same as those in Golub, et al.,
however, the equation vg = ag(xg – bg) is derived from the sample maximum likelihood
discriminator47 where bg = (⎯xmg – ⎯xng)/2. In Eqs. 1.21,1.22, bg=µiTR,m(n), where µiTR,m(n)
is simply the mean of gene (m or n) in class i. Nevertheless, the authors demonstrate
remarkably accurate predictions using the Golub, et al., data set, as well as a much
smaller data set based on a mouse model of Batten disease49.
This method was reported to have several advantages over the S2N statistic for
binary classification. First, it can be used on a small number of samples. The authors
were able to accurately predict biologically significant genes from a mouse model of
Barrett’s disease with only eight total samples. Secondly, it was able to more accurately

33
predict tumor classification for the Golub et.al.data set than the S2N statistic, Support
Vector Machines, and Neighborhood analysis. One drawback to this method is that it can
only be used to distinguish two classes, and multi-class problems are out of the range of
this approach.
1.2.3.3 Nearest Neighbor Classifiers
Nearest neighbor classifiers are a simple and powerful class of algorithms that are
based on a similarity (or distance) function between observations; in this case, classspecific gene-wise average intensities. One of the most popular among these is k-NN. For
expression profiles x = (x1,…,xg) and x’ =(x’1,…,x’g) the degree of correlation, for
example, is based on a correlation coefficient47 such as given in Eq. 1.16. Where r is the
correlation measure, xg is the expression level of the gth gene in class one, x’g is the
expression level of the gth gene in class two, and x ( x' ) is the mean expression level of
class one (two). The k nearest neighbor rule is computed as follows, (i) find the k closest
observations in the training set, and (ii) predict the class that is most common among k
neighbors47,59. The number of k neighbors can be specified by leave one out cross
validation (LOOCV) by performing for a number of k’s and retaining the one (k) with the
smallest error rate. The number of classes in T is specified a- priori. Finally k-NN
classifier is universally consistent70 if k→∞ in such a way that k/n → 0 as n →∞.
This method was used by Nutt et al., predict membership of histologically
ambiguous tumor specimens as either oligodendroglioma, a somewhat benign cancer
with favorable prognosis, or astrocytoma, a lethal brain cancer with poor prognosis. They
demonstrated a maximum accuracy of about 86% after constructing the classifier with 20
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genes. It was concluded that the gene expression data predicted prognosis more
accurately than histopathological classification.
1.2.3.4 Support Vector Machines
One class of modern techniques for data analysis are machine learning tools, such
as support vector machines (SVM), that seek to find a linear discrimination rule for data
with high dimension by non-linear re-mapping of the data into higher dimensional space.

Φ: XN → F
x → x := Φ(x)
The algorithm seeks a function that can partition F into a dichotomous space:
F → yi ∈ {±1}

XN is a input data space with dimension N and F is the feature space. In F a simple
(linear) discriminant rule (hyperplane) can be applied that would not have been

Figure 1.8. Depiction of a 2D data space re-mapped to a 3D space. In the left example,
the data are arranged in a 2D space and one class (red) is surrounded by the other
(blue). On the right a hyperplane can be specified by a linear function to separate the
classes.
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successful in XN data space69. Consider the example in Figure 1.8. On the left is a 2D
space that contains the data, clearly a linear discrimination rule would not be able to
separate the classes in the data. However, if the data are re-mapped to a 3D space, then a
linear discrimination rule can be applied to separate the two classes.
One challenge with this approach is that the dimensionality of F can increase
drastically as N increases, making computations intractable even for simple discriminant
functions. For certain feature spaces however, kernel functions can be used to compute
scalar products between data points. Some common kernel functions are listed in Table
1.1. In the binary classification setting the decision rule is given by

φ(x) = sign[f(x)]
where for data and class labels (xi,yi), i= 1,…,n a function, f(x)= h(x) + b, is sought with h

∈ HK (a reproducing kernel Hilbert space (RKHS)) and b a constant minimizing Eq.1.24

1 n
(1 − yi f ( xi )) + + λ || h ||2H K [1.24]
∑
n i =1
where (x)+ = max (x,0),‖h‖2HK is the square norm of the function h defined in the RKHS
Table 1.1: Some examples of kernel functions taken from Muller, et al.
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with the reproducing kernel function K(•,•) which measures the complexity or
smoothness of h. Finally, λ is a tuning parameter which balances the data fit and
complexity of f(x)66.
SVM is traditionally a binary classifier but it has been modified for prediction of
multiple classes (multi-class support vector machines (MSVM)) and used successfully in
class prediction problems with gene expression data66 using the data set of Golub, et al..
Lee, et al., achieved between 11% and 3% training error depending on the number of
genes used, the choice of kernel function and the preprocessing steps for the input data.
The authors also examined a data set with four classes of cancer. MSVMs correctly
classified 100% of the test samples.
Thus, SVMs and MSVMs are a viable choice for tackling the problem of using
gene expression data for class prediction. Our current implementation of SVMs is as a
binary classifier only.
1.2.3.5 Gene Shaving
A relatively simple and intuitive method of class prediction using gene expression
data is so called gene shaving. The basic concept of this algorithm is to find k-subsets Sk
of genes that maximize the variance of the gene average Eq. 1.25,
var(

1
∑ xg )
k i∈ S k

[1.25]
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Dk =

V Between
=
1
VTotal
lk

1 l
∑ ( x g − x) 2
l g =1
l

∑∑ ( x
i∈S g =1

i

[1.26]

− x) 2

as well as genes that show high coherence50.
As described in Hastie, et al., the algorithm consists of seven steps: i) beginning

Figure 1.9. Gene shaving cluster formation

with the entire expression matrix X, each row is centered to have a zero mean ii) compute
the leading principle component of the rows of X iii) shave off the proportion α
(typically 10%) of the gene having the smallest absolute inner-product with the leading
principle component iv) repeat steps ii and iii until only one gene remains, v) this
produces a nested sequence of gene clusters SN ⊃ Sk ⊃ Sk1 ⊃ Sk2 ⊃,…,⊃ S1 where Sk
denotes a cluster of k genes for which the optimal cluster size is estimated using the gap
statistic [18], vi) orthogonalize each row of X with respect to x sk , the average gene in Ŝ k
,and vii) repeat steps 1-5 with the orthogonalized data to find the second optimal cluster.
This process is continued until a maximum of M clusters are found where M is chosen a

priori50.
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The first paper to introduced this learning method was that of Hastie, et al.. In the
manuscript, the authors describe the algorithm and assert that gene shaving can be
preformed in an unsupervised, supervised or partially supervised manner. They go on to
report the supervised approach for predicting survival in patients with large B-cell
lymphoma.
1.2.3.6 Selection of Strong Feature Sets
The goal of extracting genes that are strong predictors of a relevant biological
class is the object of many classification algorithms. However, for microarray
experiments, sample sets are often small and comprise only a few members of each
relevant class. Kim, et al., employed the supercomputer facilities at the NIH and
developed an algorithm based on a perceptron that finds strong feature sets for class
prediction. Classifiers were designed from a probability distribution created from
spreading the distribution of the expression measures in a circular fashion to increase the
difficulty of classification. The algorithm was parameterized by the variance of the
circular distribution and the goal is to find gene sets whose classification accuracy
remains strong despite increased spreading of the sample data. In this case the error, as a
function of the inflated variance, gives an indication of the strength of the feature
set67,70,71. An example is given in Figure 1.10, taken from67.
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Figure 1.10. Illustration of the sample spreading method for identification of strong
feature sets. From A to D, sample variance is increased and a classification rule is
computed. Note that if spreading causes the error to increase substantially, than the
feature set is not regarded as strong.
Feature sets are identified by a heuristic search algorithm that proceeds through a
guided random walk, and is of a class of algorithms known as preceptrons. If a feature is
a member of an acceptable solution set containing a small number of features then it is
more likely to be a part of an acceptable solution using a larger set. Such algorthims can
be considered genetic search or stochastic67,70,71. In mathematical terms, identification of
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the optimum set of genes to predict class membership would require an essentially
infinite number of comparisons when n and g are both large. This method of finding
strong feature sets is useful for finding many good solutions rather than finding a best
solution70.
1.2.3.7 Prediction Analysis For Microarrays
This method, developed by Tibshirani, et al., performs automatic feature selection
by shrinking the class specific centroids72. Classification is similar to k-NN except that
class membership is determined by distance to the class specific centroid. Crossvalidation is used for generalization error estimation. Prediction Analysis of Microarrays
(PAM) will be discussed in greater detail in Chapter 3.
1.3 GLIOMA BIOLOGY AND GENETICS
The central nervous system (CNS) is comprised of two classes of cells: neurons
and neuroglia (glial cells). Neurons can be further categorized by function into motor,
sensory, and interneurons73, and are the information processing cells of the nervous
system. Glial cells outnumber neurons in the central nervous system 10 to 50 times74 but
they do not conduct nerve impulses or have a direct information processing role, rather
they play a support role for neurons73. Glial cells can be divided into macroglia
(astrocytes, oligodendrocytes, and ependymal cells) and microglia which are sometimes
phagocytic74.
Generally star shaped, astrocytes (astro= star) (cytes = cells) are the most
numerous of glial cells filling almost all of the extraneuronal space73,75. Astrocytes have
many functions including regulation and storage of potassium (K++) and removal of
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neurotransmitters such as γ−aminobutyric acid and serotonin from the local
environment74,75. Astrocytes can be subdivided as protoplasmic or fibrous depending on
the presence or absence of cytoplasmic fibers75. Protoplasmic astrocytes are
predominately found in the gray matter while fibrous astrocytes are primarily found in
the white matter75. Oligodendrocytes produce the myelin sheaths that surround axons in
the CNS. A single oligodendrocyte can myelinate between 10-15 axons doing so by
spiraling around the axon during neural development75.
Astrocytomas (ASTs) and oligodendrogliomas (ODGs) are neoplasms that stem
from astrocytes and oligodendrocytes respectively. For World Health Organization
(WHO) tumor grading occurs on a malignancy scale from one to four. In the case of
glioblastoma multiforme (GBM), (WHO grade IV), specimens have been collected that
have features of both AST and ODG tumors. In terms of prognosis, the ODGs is more
favorable than ASTs2,76, so accurate classification of histologically ambiguous tumor
specimens is of paramount importance. Gliomas generally cause symptoms (e.g. seizures)
by perturbing cerebral function, elevating intracranial pressure by either mass effect or
obstructing cerebrospinal fluid (i.e. hydrocephalus), or causing neurologic (and
sometimes endocrine) abnormalities (e.g. paralysis, sensory deficits, aberrant behavior,
headaches)77-79.
A hallmark of AST tumors is resistance to apoptosis, and by extension to most
current chemotherapeutics and radiation14 and rapid progression. If patients with resistant
tumors are given standard therapies, they suffer ineffective treatment, lower quality of
life, and sometimes devastating economic losses. There is ample evidence that surgery

42
confers little if any survival benefit and adjuvant therapies have been similarly
unsuccessful14 .Microarray technologies provide a powerful way to understand two
crucial pieces of information necessary to improve treatment of this disease: objective
classification, and the ability to obtain provide a genetic signature that can be correlated
with treatment response.
Oligodendrogliomas are associated with WHO malignancy grades II and III, the
latter being anaplastic oligodendroglioma (AOD). This tumor mainly occur in adults and
OGDs are relatively benign, however, progression to AOD can occur which carries a less
favorable prognosis. Classic ODG tumors are characterized by moderate cellularity, little
mitosis, no necrosis, and have a ‘chicken wire’ capillary morphology76. (Appendix A1).
They are usually not invasive and recurrence occurs at the primary site. The more
advanced AOD is characterized by increased nuclear pleomorphism, hyperchromatism,
hypercellularity, prominent microvascular proliferation and necrosis. Genetic lesions
include gene deletions from chromosomes 1p and 19p, over expression of EGFR, PDGF,
and PDGFR76.
Astrocytoma tumorigenesis has been proposed occur via two genetic pathways i)
a de novo pathway in which a high-grade astrocytoma develops without a previous tumor,
and ii) a progression pathway during which a high-grade tumor develops from a lowgrade precursor (II, or III). Glioblastomas can also arise de novo or from a progression
from a lower grade80. Some GBMs show predominately astrocytic features while others
show more mixed AST and OGD features76, which begs the philosophical question of
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cellular origin and / or, whether certain cells in the neoplasm re-differentiate to produce a
different glial phenotype?
Primary ASTs can be characterized by a high frequency of EGFR-gene
amplification and a low frequency of p53-gene mutation. EGFR gene amplification
occurs most frequently in glioblastomas associated with loss of a complete copy of
chromosome 1013,80. Indeed, WHO subdivisions of high-grade astrocytomas (III and IV)
have been made on the basis of frequently found genetic changes such as, p53-gene
mutation, loss of heterozygosity on chromosome arm 17p (LOH 17p), LOH 10 and
EGFR-gene amplification. Secondary / progressive tumors show a high incidence of p53
mutation, a low incidence of EGFR amplification and eventually LOH 1013. Further, p53
mutations have been identified in 60–80% (or more) of low-grade astrocytomas. This
mutation appears to have higher incidence in young patients (ages 18-40)13 IGFBP-2 has
consistently been found to be over-expressed in GBMs, and six genes, including TIMP3,

EGFR, and GDNPF, have been found to be over-expressed in 64–100% of grade II
tumors41. Seven genes, including PDGFR-α, PTN, LRP, and SPARC, were up-regulated
by at least 2-fold in 20–60% of grade II tumors41. Elevated expression of the EGFR,

MDM2, CDK4, CD44, IGFBP2, DAP-3, and laminins is well described by microarray
studies of gliomas 2,4,15,41,48,81. Leenstra, et al., utilized molecular techniques to sub-type
AST tumors (63 GBM 12 AA), for loss of heterozygosity on chromosome 10 and p53,
and EGFR amplification. They reported the results of Cox proportional hazards modeling
revealed that age and genetic subtype were significant prognostic indicators while
histological grade was not.
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Mariani, et at., demonstrate that DAP-3 was induced in the invasive rim of
Glioblastomas, and that there is considerable heterogeneity of gene expression across the
GBM tumor mass4.
The evolution of this reductionism is in utilization of high throughput
technologies such as the DNA microarray where the application of machine learning can
take advantage of the massive amounts of data. In contemporary terms, DNA (and
protein) based molecular profiling devices are poised to significantly impact the way
medicine is developed and administered.
1.4 CURRENT GLIOMA CLASSIFICATION METHODS
The Kernohan, St. Anne/Mayo (SAM-A), World Health Organization (WHO) and
TESTAST 268 protocols are the most commonly used 4-tier grading systems for
classifying grade and stage of astrocytomas, none of which is universally accepted82. This
situation has obvious inadequacies, hindering prognostic assessment, comparative
evaluation of tumors, and inter-center data comparison, while contributing to
generalization of therapy, subjective diagnosis, misdiagnosis, unnecessary medical costs,
and procedures. Survival curves generated by Karak, et al., for each of these grading
protocols were similar suggesting that results obtained by any one of the protocols can be
generalized to the others82. Interestingly, intra-classification grade-wise survival analysis
revealed differences between grades 2 and 3 or 4 but not between 3 and 4. Despite this
reported correlation between classification methods themselves, estimates of error rates
as high as 30% have been demonstrated in the literature82, decrying a need for improved
classification methods based on parameters that can be objectively defined.
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The World Health Organization (WHO) scheme is based on the appearance of
certain characteristics: atypia, mitoses, endothelial proliferation, and necrosis. These
features reflect the malignant potential of the tumor in terms of invasion and growth rate.
Tumors without any of these features are grade I (pilocytic astrocytoma), and those with
one of these features (usually atypia) are grade II (low grade astrocytoma). Tumors with
2 criteria and tumors with 3 or 4 criteria are WHO grades III (anaplastic astrocytoma) and
IV (GBM), respectively. Thus, grades I and II are the low-grade group of
astrocytomas78,79,83,84,85. Example images of the most common gliomas are shown in
appendix 1 (Table A1).
Glioblastomas are known to occur predominantly throughout the cerebrum with
infiltrative processes that can extend to the contralateral hemisphere14. Infiltrating lowgrade astrocytomas tend to occur in the lobes of the cerebral hemispheres, especially in
the frontal lobe. Pilocytic astrocytomas may occur in the frontal, temporal, and parietal
lobes and cerebellum, but they are also common in locations closer to the midline, such
as the hypothalamus, thalamus, optic chiasm, and brain stem77,79,85. In children, pilocytic
astrocytomas have a tendency to occur in the mesial structures of the cerebellum14,77,79,85.
Due to their remarkable pathology, a subset of astrocytomas comprised of
juvenile pilocytic astrocytoma (JPA), pleomorphic xanthoastrocytoma (PXA), and
subependymal giant-cell astrocytoma (SGCA), are not effectively classified by a 4-tiered
grading system such as the WHO. These tumors can have endothelial proliferation as
well as cellular atypia. Fortunately, they are slow growing and well-defined making
surgery curative in most cases14,77,79,85.
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1.5 DNA MICROARRAYS AND BRAIN TUMOR RESEARCH
Initial microarray studies of gene expression in gliomas identified differentially
expressed genes and established gene panels that were distinctive relative to
histopathological class2,23,67. Later studies focused on finding genes that could predict
tumor class2,23,67. Two reports have related gene expression patterns with survival in
gliomas2,23. Genetic correlates with survival have been described in other genetic (nonmicroarray) studies involving gliomas81. In all, eleven reports have been published
detailing brain tumor genetics through microarray analysis. These findings validate the
hypothesis that gene expression can be used to identify new tumor subclasses, yield novel
therapeutic targets and provide highly accurate diagnostic and prognostic
information2,6,13,14, 23,25,77,79,81,85,86. An important area left for consideration is how gene
expression relates to survival and other outcomes. Nutt et al., addressed this question
from the important standpoint of classifying ambiguous tumors into more appropriate
histological categories that were more accurate predictors of patient survival, but they did
not relate gene expression patterns directly to length of survival2. The question at hand is,
given a particular gene expression pattern, how long is the patient likely to survive, and
which genes can most reliably answer this question. This information will promote three
advances, i) design of DNA based diagnostic devices, ii) indication of novel
pharmaceutical targets for improved therapy, and iii) enhancement of the ability of the
clinician to plan and manage personalized treatment.
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1.5.1 Basic gene expression analysis
Three studies involving glioma genetics made histological comparisons and found
differential expressed genes simply by calculating mean expression ratios and reporting
those that were beyond a given threshold. One of the first microarray studies of glioma
genetics was conducted by Ljubimova, et al., They studied a total of 12 tissue samples
that included 5 GBMs, 2 AAII, 1 meningioma, and 2 normal brain tissues. One of the key
findings was the identification of expression patterns of laminin-8 and laminin-9 that
could be correlated with time to tumor recurrence for GBMs. In addition they detected
2345 genes with increased expression and 719 genes with decreased expression
compared to normal brain. Of these 14 were up regulated > 2-fold in all 5 GBMs. They
further demonstrated that tissue adjacent to GBM had only slight differences compared to
normal brain but that Laminin α 4 chain, keratin18, and Desmoplakin were all up
regulated compared to the GBM tumors.
Sallinen, et al., utilized microarrays and tissue chips to identify differentially
expressed genes in seven astrocytomas, three GBMs, and two specimens that represented
a primary and recurrent grade III astrocytoma20. The microarrays, from Clontech
consisted of 588 genes and were hybridized with [α-33P]dCTP labeled RT product. The
authors also prepared a tissue microarray composed of 418 individual tumor samples
(364 gliomas and 54 other types of brain tumor). They reported prominent changes in
expression fold change but did not perform any statistical tests of significance. Notable
genes reported induced in GBM vs. normal brain included SPARC, Timp-1, Timp-2, cmyc, vimentin, VEGF, and TGF-β. In addition the authors reported 10 genes
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differentially expressed between primary vs. the recurrent sample. Tissue chip analysis
revealed that ISGFBP-2 status was significantly inversely correlated to patient survival20.

ISGFBP-2 and vimentin expression characteristics as reported by the microarray analysis
were corroborated by the tissue chip immunohistochemical staining data indicating that
comparison of large average fold changes was sufficient to reveal true differences in gene
expression.
Markert, et al., demonstrated patterns of differential gene expression between four
GBMs and three normal brain specimens15. Analysis was conducted by determining
genes that were induced or repressed above a fivefold expression threshold. Using an
Affymetrix GeneChip, they identified 34 of ~7,000 transcripts that were fivefold induced
in all GBMs relative to normal brain. These genes included p53-associated protein,

MDM2, ISGFBP-5, and ISGFBP-6. They also investigated the functional manifestations
of the gene found to be differentially expressed by whole cell patch clamp. The
microarray data generated the hypotheses that voltage-gated K+ channel β3 subunit and
NMDA receptor-activated currents would be down regulated in GBMs compared to
normal brains. The authors demonstrated that the electrophysiological characteristics
were consistent with the microarray findings validating the conclusions of the microarray
analysis.
These studies demonstrate that simple fold-change analysis is an effective tool for
identifying differentially expressed genes. However, they have the disadvantage that
there is no way, outside of testing each observation, of determining the number of false
positives, similarly there are undoubtedly many genes that are regulated below the fold-
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change threshold that may be nonetheless significant. Further, this type of analysis does
not take into account that patterns of gene expression may identify important regulatory
networks, pathways, and molecular signatures.
1.5.2 Histological classification using microarray data
Histopathology has a long and successful history identifying many disease
subtypes and relating them to therapeutic strategies and clinical outcomes. Thus, most
microarray reports dealing with gliomas based their analysis on identification of
differences between defined histological classes. The methods for this type of analysis
include statistical inference, and supervised and unsupervised learning. A few groups
have developed custom algorithms to circumvent challenges posed by the inadequacies of
contemporary analytical techniques.
Huang et al., used cDNA Clonetech microarrays from identify differentially
expressed genes in 11 low grade astrocytomas relative to normal tissue6. A students
unpaired t-test was used to assess significant differential expression. Of the 1176 probes
represented on the array they found 24 genes to be differentially expressed relative to
normal tissue. These genes included tissue inhibitor of metalloproteinase (TIMP3),

epidermal growth factor receptor (EGFR), c-myc oncogene, Glia derived neurite
promoting factor (GDNPF), nm23-H4, AAD14, 60S ribosomal protein LS (rpLS), Low
density lipoprotein receptor related protein (LRP), SPARC, hBAP, pleitrophin precursor
(PTN), PDGFR-α, interferon-inducible protein 9-17 (IFI 9-27), protein kinase CLK,

teratocarcinoma-derived growth factor (TDGF1), GRB associated binder-1 (GAB1), boxdependent myc-interacting protein 1 (BINI), Tyrosine protein kinase SKY (TYRO3) ,
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lactate –dehydrogenase-A (LDH-A), Adducin 3 , guanylate kinase (Guk1), keratin type II
cytoskeletal 8 (KRT8), and CDC10 protein homologue (CDC10)6.
Rickman, et al., found 360 genes to be differentially expressed between grade IV
and grade I tumors by at least 1.5-fold in mean intensity (P < 0.01), 167 had increased
and 193 had decreased expression levels in grade IV tumors vs. to grade I tumors, 183
genes were expressed at a higher level in grade IV relative to 5 grade II astrocytomas,
and 703 genes were over expressed in glioblastomas compared with normal brain. Five
genes (ZYX, SDC1, FLN1, FOXM1, and FOXGB1) were characterized that had not been
previously associated with glioblastoma41. Significant differences between the mean
normalized intensities was determined by one-way ANOVA Hierarchical clustering as
preformed to visualize the differences in expression as a function of tumor
histopathology.
Kim, et al., developed an algorithm for selecting histological class predictor genes
in groups containing one to three members. The aim was to use a small sample set ( 25
tumors (10 GBM, 4 AA, 5 AO, 6 OGD)) and achieve superior classification error rate.
This challenge was executed by a novel process of spreading the variance of the
expression measurements for a given set of genes (3 at most)67. The algorithm they
employed is detailed in section 1.2.3.6. They demonstrated classification rules for
separating one class, say OGD, form the remaining classes, thus 4 classifiers were
developed for each set of predictor genes. While not all gene panels were reported, it is
interesting to note that there were fewer GBM discriminating genes panels, perhaps
reflecting the large degree gene expression variability in this group of
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astrocytomas23,42,48.
Van den bloom, et al., tested for genes relevant to tumor progress in 8 samples of
primary (grade II) vs. recurrent astrocytomas (grade III or IV)86. Sixty six genes were
reported significantly different for P < 0.01, and ≥ 2-fold change in expression. A total of
nine of these were corroborated by further analysis which included COL4A2, FOXM1,

MGP, TOP2A CENPF, IGFBP4, VEGFA, ADD3, and CAMK2G. It was suggested that
these gene play a role in tumor progression. Statistical inference was preformed by paired

t-tests between sample. The population distribution was estimated by permutations.
Interestingly, they reported RT-PCR fold change data and microarray fold change data
for 15 genes. Fold change measurement form these technologies corroborated well in
magnitude, contrary to reports suggesting DNA microarrays underestimate fold change
87,88,89

.

1.5.3 Survival Classification using Microarray Data
Prediction of patient survival by gene expression profiling represents a powerful
and important use of microarray technology. Currently, three glioma microarray studies
have reported gene panels that related in some way to survival. Methods used for this
type of analysis include, S2N, unsupervised clustering and class prediction. Shai et. al
reported the identification of molecular subtypes of gliomas by analysis with Affymetrix
GeneChips. They surveyed 35 glioma samples including ASTs, GBMs and OGDs. The
authors used the Affymetrix U95Av2 chip and conducted multiple analyses using the
S2N, t-test, multidimensional scaling, k-means and hierarchical clustering analysis and
were able to find genes that partitioned the samples into all relevant comparisons
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(primary vs. recurrent; astrocytoma vs. oligodendroglioma, 1yr survival vs. 3 yrs survival,
and so on)23. For survival analysis, the authors preformed a t-test on samples that
survived 1 year or less vs. survivors of greater than three years and coupled this data with
the S2N algorithm to find predictor genes. Error was estimated by cross validation, and
an error rate of 22% was reported for the survival comparison.
Nutt, et al., demonstrated that tumors with ambiguous histological features could
be accurately re-classified into a histological class for improved prognostic accuracy
(survival). Gene candidates for prediction modeling were determined by the S2N
algorithm of Golub, et al.. k-NN prediction models were constructed using different gene
panel numbers (10, 20, 50, 100, 250) derived from S2N analysis of 21 tumors that were
unambiguously classified. The model was then used to predict the membership of the
remaining histologically nonclassical specimens. Error rates determine by LOOCV were
achieve as low as 14% were reported for a gene panel consisting of 20 genes2.
Interesting, vimentin was reported as a member of the 20 gene panel.
Godard, et at., (2003) conducted cDNA-array analysis of 53 biopsy samples
comprising 24 low grade astrocytomas, 8 secondary glioblastomas, and 20 primary
Glioblastomas25. They demonstrated the application of a novel unsupervised clustering
algorithm coupled two-way clustering (CTWC)90, that finds stable clusters of genes and
samples. Clusters that were identified that were able to distinguish recurrent vs. primary
gliomas. They reported that a cluster comprised of angiogenesis genes could be used to
delineate the tumor specimens into primary versus recurrent classes and thus may
indicate survival.
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1.6 CHAPTER SUMMARY
In summary, microarray technology has evolved beyond simple differential gene
expression analysis. It now serves as a platform for multiple types of investigations
ranging from sequencing, single nucleotide polymorphism analysis (SNPS), high
throughput ligand-DNA interaction screening, and disease diagnosis.
Contemporary knowledge concerning glioma genetics has converged on some
important issues. Gene expression patterns can distinguish histological classes of gliomas
with an appreciable degree of accuracy. Gene expression in GBMs is highly variable,
which may reflect considerable within specimen heterogeneity. Gene expression can be
used to reclassify ambiguous tumor specimens more accurately into histological classes
that better reflect survival. Several important genes have been consistently identified
including genes related to invasion, motility, angiogenesis (IGFBP-2), and anti-apoptosis
(DAP-3). In fact, IGFBPs 1 – 7 have been reported differentially expressed in
gliomas2,23,41,86.
In terms of data analysis for microarrays, this body of work has been
characterized by increasing sophistication. There have been multiple, disparate,
approaches each aimed at extracting particular modes of information. Initially researchers
reported simple observations of mean fold changes, which naturally was improved upon
by performing statistical tests of significance (t-test, ANOVA). The S2N algorithm of
Golub, et al., has been employed in many studies seeking to find genes predictive of
binary classification2,23 and clustering has been used extensively.
The following chapters describe the fulfillment of the specific aims outlined in the
dissertation proposal and detail the development and validation of our biochip platforms.
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These specific aims were: i) development, ii) production, iii) validation of the C3B 10K
oligonucleotide microarray (10KO), and iv) use of this microarray to conduct a gene
expression study aimed at identifying genes predictive of astrocytoma classification. This
dissertation tells the story of how our microarray platforms were designed, fabricated,
utilized, and convey our novel contributions to the field of biochip engineering. Chapters
2 details the design and development of the 10k human oligonucleotide microarray and
makes reference to our published manuscript. Chapter 3 describes the brain tumor class
prediction study, including the design and production of our custom spotted 10K human
oligonucleotide microarray. It is widely expected that future DNA devices will be
indispensable in biotechnology and pharmaceutical research as well as disease diagnosis
and prognostic estimation.

CHAPTER 2. DESIGN AND DEVELOPMENT PARAMETERS FOR THE 10K
HUMAN OLIGONUCLEOTIDE MICROARRAY

2.0 Design of the Human Oligonucleotide Microarray
The surface chemistry was selected using parameters identified from an initial
fabrication experiment35. Although microarrays have been fabricated on many types of
surfaces22,31,35,37,91,92,93 we demonstrated that 3-glycidoxypropyltrimethoxysilane (GPS)
surface provided higher signal (foreground intensity divided by background) than other
common surfaces (Figure 2.1).
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Figure 2.1 Signal (intensity divided by background) of oligonucleotide DNA
spotted on five surfaces. The top panel is a line graph showing signal as a function
of spotting concentration. The bottom panel is a bar graph with error bars for
standard deviation. The data shows that the epoxy silane surface gave the highest
signal while spotting concentration leveled off after 0.01 µg/µl. Surface
abbreviations: DAB; amino dendrimer, PLL; poly-L-lysine, APS;

γ−aminopropaltrimethoxysilane, TEB; tris-EDTA buffer, GPS;
glycidoxypropaltrimethoxysilane. (Figure taken from35)
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The GPS surface used in conjunction with amine modified oligonucleotide probes
represented a method for covalent attachment of the oligos to the surface 22,l36,91. Because
the pH of the spotting solution was determined to be 5.2, we suggest the covalent
attachment of the oligonucleotide to the GPS was considered to proceed through an acid
catalyzed epoxide ring opening reaction. A simple schematic of the reaction of an amine-

Figure 2.2. Epoxide ring opening reaction and covalent bond formation. Amine
terminated oligonucleotide, denoted by R, is covalently attached to the
glycidoxysilane molecule.
modified oligo with the epoxide ring of a GPS molecule is depicted in Figure 2.2. Thus
the GPS surface was chosen as the substrate for immobilization of the C3B human
oligonucleotide library to 1in x 3in Goldseal (Cat# 3010, Gold Seal Products) microscope
slides. Spotting was preformed using a Cartesian PixSys 5500 microarrayer.
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The 10k human oligonucleotide microarray was designed using the MWG 10kA
human oligonucleotide library (Cat # 2190-000000, MWG) as the base gene library.
Seventeen additional “housekeeping” gene-probes and eleven probes that are also found
on the Affymetrix Hu133A chip, listed in appendix A2 (Table A2), were added to the
9,984 5’-C6-amine-terminated and HPLC purified 50-mer oligonucleotides in the MWG
set. These additional gene-probes served as internal control features and for future interplatform data comparisons; an on-going project of the C3B. Seventy-eight additional
gene-probes, which were identified though a literature search as being relevant to glioma
genetics, were also added to the MWG library. These probes were also purchased from
MWG and are listed in appendix A3 and these features are depicted in Figure 2.3.

Figure 2.3. The 10k human oligonucleotide microarray. Housekeeping genes are
denoted by colored boxes in the corners of the sub-grids. Nonspecific hybridization
controls are denoted by aqua rectangles. 3’/5’ and bacterial “spiked-in” controls are
denoted by magenta rectangles. The features are colored to show location and are not
drawn to scale.
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2.1 Fabrication methods
To functionalize the surface of the microscope slides, the slides were first solvent
cleaned in isopropanol for 1 min at 56oC followed by 1 min in acetone at 56oC.
Subsequently the arrays were dried in an Eppendorf 5804 refrigerated centrifuge by
spinning for 3 mins at room temperature then placed in a UV ozone cleaner (Model
135500, Boekel) for 10 min. The slides were then sonicated (Model 1510, Branson) in
isopropanol at room temperature for 1 min, rinsed in flowing ultrapure water, followed
by immersion in RCA (5:1:1, diH20: hydrogen peroxide: ammonium hydrioxide)
solution at 60oC for 1 min, rinsed again in ultra-pure water, and dried by centrifugation.
The cleaned, dried slides were placed in a 0.1% v/v solution of toluene and GPS for
surface modification at 40oC for 30 min. After this incubation, the slides were washed in
anhydrous toluene, and cured at room temperature for 48 hrs.
The printing script, executed by the Cartesian software, was custom written in
house exclusively for the production of the 10KO such that the base library, including the
78 supplemental oligos was printed first followed by placement of the control features.
Contact printing was performed under 50 % relative humidity using eight silicon
spotting quills (Parallel Synthesis). Oligos were spotted at 25 mM in a spotting buffer
(pH = 5.2) of 0.75 M betaine and 1.5 X SSC as reported in Diehl et al.. The spotting
concentration was specified by the MWG protocol as 50 mM, but was reduced to the 25
mM concentration on the basis of information gleaned from the initial microarray
fabrication experiment35 (Figure 2.1). The primary array was printed in duplicate on each
slide yielding 21,168 total features. The primary and replicate sub-arrays were divided
into 4 x 12 (48) sub-grids of 21 x 21 (441) spots each (Figure 2.3).
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2.2 Quality control features
The quality control features enabled quality prescreening of the hybridized
microarrays. These features were analyzed using the NQC R script written specifically
for the 10KO. At the time the 10KO was designed, the housekeeping genes were thought
to be useful for normalization of microarray data, this notion has been largely
debunked29,56. Currently, these probes primarily serve to align the quantification grid of
the Quantarray software.
The probes for the bacterial genes BioB, BioC, PheB, and ThrC (Table A2), are
implemented for positive control and uniformity of the hybridization event. They are
spotted at a concentration of 25 mM in row 21, columns 1-4 of each sub-grid, and Cy3
(MWG) labeled complimentary targets were spiked into the hybridization solution at the
final concentrations of 500pM, 250pM, 125pM, and 75pM respectively such that it was
expected to observe a linearly decreasing foreground intensity from these spots. To test
for this, a lack-of-fit test61 was applied to the Log2 intensity values of these spots. A pvalue < 0.01 was considered as evidence against the appropriateness of the regression
model i.e., lack of fit.
The BioD series of 10 spots, printed at concentrations in a two fold dilution
starting at 200mM were used to obtain a value for data filtering based on the linear
regression at the intensity on the y-axis corresponding to the graphical intersection at
25mM (Figure 2.4). This information was used to remove spots that displayed intensity at
the non-specific hybridization intensity threshold.
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Figure 2.4 Example graph for linear regression of BioD spots. The intersection
of Log2 intensity and spotting concentration (25µM) was used to determine the
value at which to filter the data for nonspecific hybridization.
Finally, there were six spots that probe for 3’ and 5’ ends of the transcripts for
GAPDH, ISGF, and Beta Actin. These spots report the fidelity of the RT reaction by
indicating that the distal (5’) ends of mRNA transcript are copied with the same
abundance as the 3’ end. For these spots the I3’/I5’ = IR is 0 ≤ IR ≤ 3.0, where I is the
foreground intensity from the spot. Arrays with poor IRs are typically discarded from
further analysis.

CHAPTER 3. MALIGNANCY GRADE AND OUTCOME PREDICTION IN
HUMAN GLIOMAS BY DNA MICROARRAY ANALYSIS

ABSTRACT

We report the identification of predictive gene panels for tumor grade and
survival by microarray analysis of 64 glioma samples including WHO grades I, II, and IV
for astrocytomas, and grades II and III for oligodendrogliomas. We demonstrate that
transcriptomic profiles are able to distinguish tumor grade and predict survival class in a
comprehensive set of human gliomas. Prediction analysis of microarrays (PAM)
identified a 22 gene panel capable of distinguishing glioblastoma multiforme (GM)
tumors from oligodendrogliomas (OL) SAM censored survival followed by k-nearest
neighbors (k-NN) class prediction revealed simple survival classes for gliomas. Analysis
using PAM identified 22 genes with a false discovery rate (FDR) = 0.0 that achieved 94%
classification accuracy among GMs and OLs. Survival analysis followed by k-NN class
prediction achieved ~84% classification accuracy for a 3yr simple survival rule with a 50
gene panel, FDR = 0.24. This study supports the use of microarrays in molecular
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diagnosis and prognostic estimation for human gliomas for the purposes of patient
counseling and treatment planning.
3.0 INTRODUCTION
The instantaneous transcript abundance profile data captured by the DNA
microarray has been shown to accurately predict histological class and survival in
multiple cancers2,8,50,62,64,65. We applied this technology to investigate gene expression in
a comprehensive set of human gliomas. Gliomas are a devastating form of brain cancer,
leading to >17,000 deaths per year in the United States80. Patients diagnosed with
glioblastoma multiforme (GM) have a mean survival of ~52 weeks13,94 and brain cancers
are one of the leading causes of death in children80. Histologically ambiguous explants
are associated with a 30% misclassification rate2,82,95, and current treatments for gliomas
have failed to significantly increase quality of life or survival for the past 25 years13.
Efforts to understand the molecular etiology of this disease have been facilitated
by use of DNA microarrays6,4,15,17,20,23,41,48. Initial work identified differential gene
expression by a mean Log2 fold-change (FC) threshold (i.e., FC = 2). This revealed genes
such as ISGFBP-2, laminin-8,9 SPARC, TIMP-1,2, c-myc, vimentin, VEGF, PDGFR, and

TGF-β, and ISGFBP-1,2,5,6 to be differentially expressed in gliomas relative to normal
brain15,20,48. More sophisticated analysis has revealed distinct patterns of gene expression
in gliomas, high variability in GMs, and demonstrated clusters of genes involved in
angiogenesis, cell motility, and progression6,,41,67,86. Class prediction and survival analysis
has revealed gene panels that are capable of reclassifying previously ambiguous gliomas
into a more appropriate survival class. Novel clustering methods have identified gene
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expression differences in primary vs. recurrent gliomas which may indicate therapeutic
targets for treatment2,41,65.
A major future application of DNA microarray technology is the development of
a targeted, low density, DNA based diagnostic/prognostic devices. Development of such
devices will depend on delineation of an adequate panel of genes that relate to molecular
subtype for diagnostics, and outcomes for prognosis96. We seek to identify such gene
panels for diagnosis of malignancy and prognosis of glioma patients through microarray
analysis of glioma samples.
In the current investigation, 62 human glioma samples representing 5 WHO
malignancy grades were analyzed using the custom spotted C3B 10K oligonucleotide
microarray (10KO). To identify gene panels that were predictive of malignancy grade
and survival, feature selection, based on gene expression values, was preformed using
methods implemented in prediction analysis for microarrays (PAM)72 (malignancy grade)
and univariate Cox proportional hazards modeling (survival) using censored survival
data. Class prediction models were built for malignancy grade (shrunken centroids)72 and
simple survival rules (k-NN). It is broadly anticipated that transcriptomic information
about disease etiology will enable the development of personalized treatments and
drastically improved therapeutic quality2,25,61,67.
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3.1 METHODS AND MATERIALS
3.1.1 Sample acquisition
‡

Tumor tissue was prospectively collected in the operating room in accordance

with VCU IRB-approved protocols (VCU IRB#3031). Samples were snap-frozen in
liquid nitrogen within 5 minutes of excision and stored at -86ºC until ready for sectioning
and extraction. IRB approved glioma samples were acquired from the VCU medical
center campus Broaddus/ Filmore tumor bank and transported to the C3B laboratory on
dry ice. Received samples had associated sample ID, histopathological category, and
mortality time/ time to censor. For total RNA extraction, tissues were pulverized to a fine
powder in pre-cooled nuclease-free mortar and pestle, and pulverized tissue placed
directly in TRIzol reagent (Invitrogen, 15596-026) and processed according to
manufacturers specifications. Total RNA extraction was followed by clean up by RNeasy
columns (Qiagen Inc., Valencia, CA) according to the manufacturer’s protocols. Samples
were stored at –80oC until removed for reverse transcription.
The quality of the total RNA sample was assessed using a 2100 Bioanalyzer and
RNA 6000 LabChips® (Agilent, Palo Alto, CA) such that the measured 28s to18s
ribosomal quantity ratio ≥ 1.1. The sample set was comprised of six histopathological
classes: 25 glioblastomas (GM), 9 anaplastic astrocytomas (AA), 10 pliocytic
astrocytomas (PA), 10 oligodendrogliomas (OL), and 10 anaplastic oligodendrogliomas
(AO). These samples are listed in appendix 5.

‡

The work described in this paragraph was preformed by our collaborators: Dr. Tim Van Meter, and the
Dr. William Broaddus and Helen Filmore research group.
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3.1.2 Experimental design
The hypothesis that a subpopulation of genes within the C3B gene library can be
used delineate glioma stage, grade, and patient outcome (survival) was tested using data
derived from a standard reference design (Figure 1.3). This design gives several
advantages: it allows for open ended data collection (extensible), it enables statistical
estimation of all main effects and higher order interactions with the same precision, it
allows for large numbers of samples without increasing the complexity of analysis, and
down stream clustering analysis is greatly simplified over designs such as a
loop design45,67,97. This design can also be thought of as a randomized block design99
where each array represents a block, and arrays are randomized with respect to sample.
For this design, a reference sample (r = 1) and a tumor sample (t = 62) are cohybridized to each array such that each array is interrogated by the same reference but a
different tumor sample. Stratagene Human Reference total RNA was used as reference
total-RNA and was labeled with Alexafluor 647. Each tumor sample was labeled with
Alexafluor 555.
3.1.3 Reverse transcription, array hybridization, and labeling
Tumor total-RNA was reverse transcribed according to standard protocols. The
Genisphere labeling kit (Genisphere Cat # H500100 and H500110) was used to
fluorescently label the reverse transcribed and hybridized oligonucleotide targets. This
labeling method utilizes a two-step approach. The first step was the hybridization (for 16
hr) of the reverse transcription (RT) product to the oligonucleotide probes on the surface
of the array. The RT product, was synthesized using Genisphere primers that contain a
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linker region that binds to the labeling dendrimer in the second hybridization step (4 hr).
The labeling dendrimer consisted of a third generation DNA dendrimer that contained
~950 Alexafluor molecules, and the relatively large amount of fluorescent molecules on
the dendrimer molecule allowed for the use of extremely small amounts starting material.
For the Genisphere labeling method, 0.5 – 2.0 µg/µl of total-RNA are recommended and
by comparison, alternative labeling methods such as aminoallyl or dyeconjugated
nucleotide labeling require 15 –25 µg/µl of total-RNA. Thus, the Genisphere reagents
were chosen for this experiment chiefly because of limited tumor sample total-RNA
availability. It has been noted that earlier generation Genisphere products have been
associated with a more limited ability to detect fold changes (sensitivity) compared to
aminoallyl or dye conjugated nucleotides, however, the current generation products used
in this experiment have not been evaluated for their sensitivity.
Stratagene Human Reference total-RNA (Cat # 740000) was chosen as the
reference RNA used to hybridize against the sample cDNA and was always labeled with
Alexafluor 647. The reference cDNA was reversed transcribed in paired-withsample10µL reactions then pooled before aliquoting into microcentrifuge tubes
containing the tumor RT product. A total of 1µg of tumor total-RNA and reference totalRNA was used for each RT reaction. The RT reactions were preformed in a Scigene heat
block with heated bonnet at 52oC using Superscript III (Invitrogen, Cat# 18080-044)
reverse transcriptase in a volume of 10µL. Hydrolysis of RNA and neutralization were
preformed according to the Genisphere protocol.
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Hybridization and labeling took place in Telechem hybridization cassettes using
Lifterslips (Erie Scientific, Cat# 25x60I-2-4789). Sealed cassettes were incubated for 16
hrs in an oven at 520C for the cDNA hybridization step. The hybridization buffer
consisted of 30µl of 2X Enhanced hybridization buffer (Genispere Cat # CW31200S25),
14 µl each of sample and reference RT product solution, in a total volume of 60 µl.
Spiked-in probes (2µl of 100X Cy3 labeled oligonucleotides) complementary to the
control features BioB, BioC, ThrC, and PheB was included in the hybridization solution
at 500pM, 250pM, 125pM, 67.25pM respectively. The cDNA hybridization solution was
pipetted under a Lifterslip that was placed over the array and wrapped in parafilm prior to
preparation of the hybridization solution. Post hybridization, arrays were washed for 10
min in medium stringency wash buffer (2X SSC and 0.1% SDS) at room temperature
then rinsed 10 times in 2X SSC buffer according to the Genisphere protocol. The arrays
were then dried in an eppendorf centrifuge at 1300 RPM for 3 minutes.
Dried arrays were covered with a Lifterslip, wrapped in parafilm and placed back
into the hybridization cassette for the labeling step (3DNA hybridization). The 3DNA
labeling solution consisted of 30 µl of 2X SDS based hybridization, 3 µl of Alexafluor
555 labeling reagent (Genisphere kit component), 3 µl of Alexafluor 647 labeling reagent
(Genisphere kit component), 1 µl of anti-fade reagent, and 23 µl ultrapure water. The
labeling solution was pipetted under a Lifterslip and the sealed hybridization cassette was
placed in a lab oven 52oC for 4 hours. Washing and drying procedures were carried out in
the same manner as in the cDNA hybridization with the exception that the initial wash
was 5 mins with 100 µM dithiothreitol (DTT) (Invitrogen, Cat # Y00147) added to the
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wash buffers to protect against Alexafluor 647 dye fading (Figure 3.1). All washes were
preformed according to Genisphere protocols.
3.1.4 Image acquisition and quantification
Hybridization times were staggered such that arrays completed their labeling
hybridization period in 15 min intervals. This was done to minimize AlexaFluor 647 dye
fading99 (Figure 3.1) and arrays were scanned immediately after drying by centrifugation.
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Hybridized microarrays were scanned in a ScanArray Express microarray scanner
under 90% laser power, 80% PMT gain and 10µm scan resolution. Scanned images were

Alexa 647 Intensity
t = 10 min

Alexa 647 Intensity
t = 30 min

saved as *.tif files for image quantification. Acquired images were quantified using the

Alexa 647 Intensity
t = 0 min

Alexa 647 Intensity
t = 0 min

Figure 3.1. Scatter plots of AlexaFluor 647 dye fading. Intensity data from the
AlexaFluor 647 channel from the initial scan plotted against data from the same array
scanned after 10 minutes (left panel), and after 30 minutes (right panel) of dark
storage under ambient conditions. The initial scan data were plotted on the x-axis and
the subsequent scan data were plotted on the y-axis. Notice, as time progressed, the
intensity distribution shifted toward the initial scan data. Red dots indicate a two-fold
difference.
QuantArray software from Perkin Elmer. The adaptive circle method of foreground
intensity pixel segmentation was used to define the margins of the spots and spots were
located using the nominal location feature, i.e., spots were not located using the

71

automatic algorithm. The resulting quantification output was saved as ANSI tab delimited
text files.
3.2 ANALYTICAL METHODS
3.2.1 Quality control and data normalization
Prior to the analysis of the raw data files were modified in two ways, i) the text
files were deconstructed such that two files were created from each initial data file
(decon), and ii) the primary and replicate gene intensity values were averaged (geneaveraged). Recall that the 10KO contained a primary and secondary array yielding two
measurements for each gene (Figure 2.3), 10584 measurements from the primary array,
and 10584 measurements from the replicate array. For the deconstructed (decon) files,
this translates into two columns (vectors) in the expression matrix Xdecon for each sample.
This essentially increases the number of measurements by two, and was done to increase
the sensitivity of the feature selection for the survival analysis. This paradigm was chosen
based on statistical theory33. Malignancy classification was preformed on gene-averaged
data.
Pre-analytical data treatment proceeded in four steps, two quality control steps
and two normalization steps. First, the data were prescreened by NQC (2.3) to detect
arrays that performed poorly. This data is given in Appendix 4. Correlation among all
pairs of arrays was calculated on a per channel basis, this data is given in Table A6 in
(Appendix 6). The correlation metric used was,

ρ x, y =

cov( X , Y )
σ X ⋅σ y

[3.1]
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where σ = the sample standard deviation.
Prior to normalization the log2 ratio of sample / reference was calculated which
serves to control for differences in immobilized probe concentration and spatial effects.
The data were then normalized in two steps. First arrays were regularized by standard
deviation45. This normalization is preformed based on the assumption that all spots within
each subgrid on an individual microarray and all spots within each microarray in a set of
microarrays should have the same standard deviation for log2 Iis/ Iir, where I is the
measured intensity for spot i in the sample channel (s) and the reference channel (r).

Figure 3.2. The effect of standard deviation regularization and LOWESS
normalization. Ratio (log2[Is/Ir]) (y-axis) vs. intensity (log10[Is-Ir]) (x-axis) plots of
array 12-40, sample aa9. Blue dots indicate intensity distribution of spots before
normalization, red dots indicate the intensity distribution after normalization. Left
plot is of standard deviation normalization and the right plot is of LOWESS
normalization.
Standard deviation regularization scales the sample and reference channel intensities for
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each spot such that the spots within each sub-grid or all spots within each microarray in
an experimental set will have the same standard deviation for log2 Iis/ Iir. This adjustment
was applied to sub-grids within an array to adjust for uneven hybridization and between
arrays to normalize for array-to-array differences (i.e., production lot).
Finally, the data were normalized by sub-grid LOWESS normalization32 with f =
0.4. This normalization was applied to correct curvature in the ratio vs. intensity (RI)
plot (Figure 3.2), and to shift the intensity distribution to center around zero on the RI
plot. Curvature in the RI plot indicates a dependency of log2 Iis/ Iir ratio distribution on the
measured intensity value. Shifting the intensity distribution toward zero on the RI plot
helps remove the dye dependent intensity bias of the distribution. Data normalized in this
way were used in all subsequent analyses. These normalizations were preformed using
the MIDAS program45.
3.2.2 Feature selection and class prediction
Feature selection is a general term used here to indicate the method by which
features (genes) are selected for further analysis. In the context of microarray data, many
genes provide little information about a particular biological condition so it is necessary
to develop a means for selecting genes that are relevant to the question at hand. Some of
these methods previously employed by the microarray community are described in
chapter 1. The methods used for the study described in this chapter are PAM, (for
malignancy grade), SAM Cox proportional hazards modeling followed by k-NN
classification (for survival).
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3.2.2.1 Prediction analysis for microarrays
Prediction analysis for microrrays performs automatic a feature selection via
shrinking the class specific centroid. This removes genes that fall within the limits of the
threshold parameter (∆)72 which controls the amount of shrinkage. Classification is
preformed by calling unknown sample xn* a member of class i by computing the distance
to each class specific centroid and giving membership to the nearest centroid. For
convenience, the method described below is taken from Tibshirani et al. For a more
verbose treatment refer to the manuscript72.
Briefly, the centroid for gene expression data can be calculated for each class and

Class 1Centroid

Class 2 Centroid

Class 3 Centroid

Gene 1
Gene 2

Gene 3
∆1 ∆2

∆1 ∆2

∆1 ∆2

Fold Change

Fold Change

Fold Change

Figure 3.3. Illustration of class-wise gene expression centroid. Each class has a centroid
based on gene expression values. The values of ∆ control the amount of centroid
shrinkage. Here, two values of ∆ are depicted, and for ∆2 (in class 3) the amount of
shrinkage excludes gene 2 from consideration. This removal is the feature selection step.
is illustrated in Figure 3.3. If xgs is the expression value for the gth gene where g =
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1,2,…,l and sth sample where s = 1,2,…, n, and there are 1,2,…,c classes such that the
class labels are denoted by ic for the n samples in class i, then the gth component of the
centroid for class i is x gi = Σ s∈Ci xgs / ni .
Given

d gi =

xgi − xg
[ 3.2]
mk ⋅ (qg − qo )

where

qg2 =

1
∑
s−i i

∑ (x

s∈C i

gs

− xgs ) 2 [ 3.3]

and mi = 1 / si + 1 / s makes mi·qg equal to the estimated standard error of the numerator
in dgi. The value for qo is set such that it is equal to the median value of qg over the set of
genes to remove large values of dgi that arise from chance by low expression levels as in
the SAM algorithm39. Thus, dgi is essentially a t-statistic and the PAM method shrinks
each dgi toward zero ( by specifying the ∆ parameter) giving d’gi and yielding the
shrunken centriods. This can be expressed as,
xgi′ = xg + mi ( q g + qo ) d gi′ ⋅

[3.4]

This method of shrinkage can be described as soft thresholding and is described in the
following equation,
d gi′ = sign ( d gi )( d gi − ∆ ) +

[3.5]
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where the + indicates to take the positive part (t+ = t if t>0 and zero otherwise)72. It can be
seen in Eq. 3.5 and Figure 3.3 that the value of ∆ sets the threshold for the amount of
centroid shrinkage.
The ith discriminant score δi is calculated relative to the ith shrunken centroid and
is corrected by the class prior probability72. The classification rule specifies the class
membership choosing the discriminant score that minimizes the distance of the gth test
observation to the shrunken centroid.
The latter is a type of classification algorithm that is similar to k-NN with the
exception that class membership is determined as a function of the class specific centroid,
rather than the k nearest distances to individual class members.
3.1.2.2 SAM censored survival
Survival analysis is a class of methods used for time-to-event or failure time
analysis. In engineering these methods are used to estimate such quantities as product
life expectancies. In the medical field, they are used to estimate survival time of
individuals given data such as stage of disease. The survivor function at time t is the
proportion of units in the population for whom T > t. For instance, the proportion of
individuals still alive at age t = 95 years. This function can be denoted S(t)

S(t) = P(T>t) = 1-P(T≤t)

[3.6]

The most widely used survival model is the Cox proportional hazards model100,101
whose general form is given in Eq. 3.7.

h(t) = [h0(t)] e(βX)

[3.7]

or equivalently

h(t) = [h0(t)] exp( β1X1+ β2X2 + … βnXn)

[3.8]
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This is a semi-parametric exponential regression function for the hazard at time t, h(t).
The value of the βs are estimated using partial likelihood. It can be seen from Eq.
3.7 that when X= 0 the hazard h(t) equals the baseline hazard h0(t). For a single
dichotomous independent variable such as 0 for a censored observation and 1 for death,
dividing each side by h0(t) gives the hazard ratio, which indicates the expected change in
the risk of the event when X1 changes from 0 to 1.
The Cox model has been conveniently implemented in the TIGR MeV software
SAM module where the SAM distance metric d(g) of Eq. 1.14 for the Cox model is

d0(g) = h(t)g = [h0(t)g] exp( β1gX1g )

[3.9]

This software accepts as input time-to-death, time-to-censor and gene intensity xig
and finds genes that are significantly related to survival according to the value of

∆ selected. Once a list of genes significantly related to survival is determined, any value
of t (days) can be selected for defining a classification rule. Ideally, we would like to find
the minimum number of genes that achieves the lowest classification error rate.
We chose four biologically arbitrary classification rules (i.e. +/-1 yr survival) to
select a list of genes that could classify samples with a low error rate. This, of course,
throws out information but is nevertheless useful for giving glioma patients and clinicians
information for personal and treatment planning. The k-NN classifier that was used to test
the ability of the genes selected using the survival model was described in detail in
section 1.2.3.3, and its error rate was estimated using LOOCV.
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3.1.3 Analysis procedure for malignancy grade
Gene-averaged files were formatted for input into the PAM software package.
This package operates in the R environment103 and allows estimation of generalization
(classification) error (ε) by v-fold cross validation, for all analyses v = 10.
The v-fold procedure involves partitioning the sample set in to v fractions,
calculating the classification error rate with v – 1 fractions, as a function of the threshold
parameter ∆, and repeating this procedure for all v fractions. The error rates are averaged
and the variance, due to the differences in error estimates among the v iterations, is also
calculated.
Plots for cross validation error, and the false discovery rate (FDR) were
constructed, and gene lists were generated for selected values of ∆ (Figure 3.5). The 22
gene list of GM vs. OLs was reported in the results section and was the gene list
associated with the lowest FDR and ε.
Analysis was initially conducted on all sample types, and then preformed for
selected pairings. The pair-wise comparisons were preformed to select genes from
commonly misclassified gliomas. For instance, a histopathologist is unlikely to confuse a
PA from a GM, but an AA to GM comparison is more prone to subjective diagnostic
error. The specific pair-wise comparisons were GM vs. AA, GM vs. AO, and GM vs. OL.
3.1.4 Analysis procedure for survival
The MeV software package45 was used for survival analysis. Survival was
modeled using only 80% (49) of the samples, the samples not included are listed in Table
3.1. Class prediction models were built using a k-nearest neighbors (k-NN) classifier
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using 100% (62) of the available samples. Several classification rules (i.e., survival times:
+/- 365 days, 740 days, 1080 days) were applied to genes panels of 100, 50, 20, and 10
genes. Genes were selected for panel inclusion as ranked by the value of do (Eq. 4.9).
This was done to determine if a reduced suite of genes, fewer than detected significant
could be used to build a class predictor. The reduced gene panels were evaluated
according to their LOOCV classification error.
This analysis was conducted twice, once with gene-averaged files, and a second
time with decon files. This approach was adopted due to the high observed FDR rate after
Table 3.1. Samples not included in survival analysis.
Sample HistologyA

Survival TimeB

1

AA

69 d

2

AA

735 c

3

AO

83 d

4

AO

1739 c

5

GM

70 d

6

GM

1103 c

7

GM

421 d

8

OL

1511 d

9

OL

300 d

10

PA

1008 c

11

PA

2402 c

12

PA

1851 c

Index

A

Sample histology, AA = anaplastic astrocytoma, AO = anaplastic

oligodendroglioma, GM= glioblastoma multiforme, OL =
oligodendroglioma, and PA = pilocytic astrocytoma.
B

Survival time is reported for each sample with letter codes: d = dead , c =

censored.
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gene-averaged survival analysis (Section 3.1.1) because it was expected that the
additional data would increase the sensitivity to detect expression differences that were
significantly related to survival. After each model fitting and validation step, the genes
common to our data and the SMD data set were used make predictions of class
membership on the SMD data set. This was done to check the accuracy of our predictive
gene panels against a published data set104. We were able to obtain 20 GM samples and
associated survival data. Since these data were limited in terms of their survival time
distribution, only the +/- 1yr survival rule was tested. The arrays used to assay these
tumors consisted of ~40,000 cDNAs, with some gene replications.

3.3 RESULTS
3.3.1 Initial cluster analysis
To determine if sample and gene clusters relating to biological variation in the
data could be identified through hierarchical clustering, the data were filtered by low
intensity resulting in ~1400 genes, then the top 200 (~ 2% of genes) remaining genes
with the highest variance were retained. The intensity filter was applied such that spots
with intensity lower than a specified cutoff were removed. The number of genes removed
was determined by iteratively filtering genes by intensity then filtering the resulting genes
by retaining those with the highest variance, then constructing the cluster map. For most
iterations, the resulting clustering result failed to indicate biologically relevant clusters
(i.e., by sample class). Only after drastic reduction in the genes by first applying the
intensity filter, were relevant clusters obtained. Others have performed clustering on the
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bulk (i.e., > 200) of the genes present on their microarrays and obtained results that
followed expectation (i.e., clusters formed according to sample class or subsets within
class)20,23,41,104.
For the data presented here, the average linkage method used to produce sample

Figure 3.4. Unsupervised clustering of 200 genes after low intensity and variance
filtration (top 200 genes (2%)). Clusters were generated by Pearson correlation and
average linkage. Classes are color coded; green = NB, dark blue = GM, soft blue =
AA, aqua = PA, Dark red = AO, and pink = OL. Low-grade malignancies clustered
predominately on the right, high-grade malignancies in the middle, and the normal
brain specimens occupy a cluster on the left.
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and gene clusters, and Pearson’s correlation was used as the similarity metric. Clusters
formed somewhat according to malignancy grade as shown in Figure 3.4. As expected,
the NB samples clustered together.
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3.3.2 Class prediction of malignancy grade
3.3.2.1 Classification of all classes
To determine if gene panels could be identified that could distinguish all five
malignancy grades from one another, the microarray data was analyzed using PAM. As a

Figure 3.5. Misclassification rates and FDR curves for all five glioma classes. The
top left plot shows the average misclassification rate (y-axis) of the 5 glioma classes
with variance bars. The bottom left plot shows individual mis-classification rates as
a function of number of genes and ∆ for each of the glioma classes. The number of
genes is given on the top x-axis and ∆ is given on the bottom x-axis. The right panel
is a plot of the FDR (y-axis) as a function of the number of genes (bottom x-axis),
and the value ∆ (top x-axis). Line colors in the left bottom plot indicate the
following: dark red = GM, green = OL, blue = PA, black = AO, and grey = AA
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definition, the overall error rate (ε) is the average of each class-wise error rate. The

class-wise error rate is the number of times a member of a particular class was classified
into an alternate class. This analysis did not indicate a single suite of genes capable of
distinguishing all tumor classes with a low ε (i.e., > 30%).
However, this analysis did provide the first indication that the best classification
was achieved between GM and OL tumors. Specimens for PA, AA, and AO were not
easily distinguishable. The feature selection step was associated with a high FDR, for
instance, at ∆ ∼ 0.9 (Figure 3.5 top x-axis, right panel), the median FDR was ~ 75%
(Figure 3.5 y-axis, right panel), for ~ 1900 genes (Figure 3.5 bottom x-axis, right panel).
The lack of sensitivity for feature selection can also be observed in the high
Table 3.2. v-fold-crossvalidation error rates for all classes. For the contents of this
Table, ε = 0.5, for ∆ = 1.0 and ~2300 genes.
Class

AAA

AOA

GMA

OLA

PAA

Class-wise εB

AAA

5

3

0

1

0

0.44

AOA

0

1

4

4

1

0.9

A

2

2

14

2

4

0.42

A

0

3

0

5

1

0.44

A

0

0

4

1

5

0.5

GM
OL
PA

Overall εC
A

0.48

Tumor class designations.

B

The error rate is reported in the far right column.

C

The over-all error rate is the average of the values for each individual class-wise

error rate.
misclassification error rate, which achieved its optimum overall misclassification error, ε
= 0.48, for ∆ = 1.0 and ~2500 genes. Individual error rates are summarized in Table 3.2,
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and it can be seen that the tumor classes most likely to be classified correctly were the
GMs and the OLs. The AO tumors were most likely to be misclassified followed by the
AAs.
3.3.2.2 Class prediction on selected pair-wise comparisons
In a clinical setting, the most relevant need of improving classification occurs
among malignancies that are most likely to be misclassified and also have an appreciable
disparity in prognosis. Three such comparisons were defined as GM vs. AO (Figure 3.6),
GM vs. AA (Figure 3.7), and GM vs. OL (Figure 3.8). In practice, lower grade
malignancies are often given elevated status as a conservative measure to ensure the
patient is not denied aggressive treatment2.
The misclassification and FDR plots for these comparisons are given in figs 3.6 –
3.8, and the individual misclassification rates are given in Table 3.3. It can be seen from
this data that the comparisons of GM vs. AA, and GM vs. AO were not as reliable given
Table 3.3. Individual v-fold-cross validation error rates for selected pair-wise
comparisons.
Comparison

A

Threshold

Overall ε

GM ε

B

C

Other Class ε

# Genes

Median FDR

GM vs. AA

1.2

0.24

0.08

0.66

~420

0.5

GM vs. AO

1.4

0.33

0.22

0.60

~150

0.5

GM vs. OL

2.0

0.09

0.13

0.0

~22

0.0

A

The value of ∆ is specified and all other parameters are given as a function of ∆.

B

The overall ε is the average of the individual ε’s from the binary classification.

C

The “Other Class” column gives the ε for the other member of each comparison (i.e.,

AA, AO, or OL).
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the high FDR and class-wise error rates. The comparison of GM to OL did yield a set of
genes that were capable of classifying the tumors with a low ε and was associated with a
low FDR. These genes are listed in Table 3.4.

Figure 3.6. Misclassification rates and FDR curves for GM vs AO glioma
specimines. The top left plot shows the average misclassification rate (y-axis) of the 5
glioma classes with variance bars. The bottom left plot shows individual misclassification rates as a function of number of genes and ∆ for each of the glioma
classes. The number of genes is given on the top x-axis and ∆ is given on the bottom
x-axis. The right panel is a plot of the FDR (y-axis) as a function of the number of
genes (bottom x-axis), and the value ∆ (top x-axis). Line colors in the left bottom plot
indicate the following: green = GM, and red = AO.
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Figure 3.7. Misclassification rates and FDR curves for GM vs. AA glioma
specimines. The top left plot shows the average misclassification rate (y-axis) of the
5 glioma classes with variance bars. The bottom left plot shows individual misclassification rates as a function of number of genes and ∆ for each of the glioma
classes. The number of genes is given on the top x-axis and ∆ is given on the bottom
x-axis. The right panel is a plot of the FDR (y-axis) as a function of the number of
genes (bottom x-axis), and the value ∆ (top x-axis). Line colors in the left bottom
plot indicate the following: green = GM, and red = AA
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Figure 3.8. Misclassification rates and FDR curves for GM vs. OL glioma
specimines. The top left plot shows the average misclassification rate (y-axis) of the
5 glioma classes with variance bars. The bottom left plot shows individual misclassification rates as a function of number of genes and ∆ for each of the glioma
classes. The number of genes is given on the top x-axis and ∆ is given on the bottom
x-axis. The right panel is a plot of the FDR (y-axis) as a function of the number of
genes (bottom x-axis), and the value ∆ (top x-axis). Line colors in the left bottom
plot indicate the following: red = GM, and green = OL.

These results indicate that the gene expression data collected during this
experiment is well suited for predicting class membership among GM and OL tumors.
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However, the data does not appear as adequate for predictions of class membership

Table 3.4. Gene panel consisting of 22 genes. Top 22 genes yielding a low v-foldcrossvalidation error rate between GM and OL tumors. Here ∆ = 2.2.
Gene Name
1 NM_003380_1 vimentin VIM
2 NM_000582_1 secreted phosphoprotein 1 osteopontin bone sialoprotein I
3 NM_001553_1 insulin like growth factor binding protein 7 IGFBP7
4 NM_021103_1 thymosin beta 10 TMSB10 mRNA
5 NM_004202_1 thymosin beta 4 Y chromosome TMSB4Y
6 NM_000146_1 hypothetical gene supported by BC002991 NM_000146
7 NM_021025_1 homeo box 11 like 2 TLX3 mRNA
8 NM_004048_1 beta 2 microglobulin B2M
9 NM_001276_1 chitinase 3 like 1 cartilage glycoprotein 39 CHI3L1
10 NM_025126_1 hypothetical protein FLJ21786
11 NM_004203_1 membrane associated tyrosine and threonine specific cdc2 inhibitory kinase
12 NM_025024_1 hypothetical protein FLJ14082
13 NM_016610_1 Toll like receptor 8 LOC51311
14 NM_004355_1 CD74 antigen invariant polypeptide of major histocompatibility complex
15 NM_001444_1 similar to fatty acid binding protein 5 psoriasis associated
16 AB061838 ribosomal protein S3 2
17 Transcription elongation factor A SII 3
18 NM_003254_1 tissue inhibitor of metalloproteinase 1, TIMP1
19 NM_001780_1 CD63 antigen melanoma 1 antigen CD63
20 NM_002045_1 growth associated protein 43 GAP43
21 NM_018601_1 hypothetical protein PRO1446
22 NM_003927_1 methyl CpG binding domain protein 2 MBD2

among the other two comparisons.
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3.3.3 Class prediction of patient survival
Genes whose expression related to survival were identified using SAM censored
survival available in the TIGR MeV software package. A unique feature of SAM is that it
allows the user to select the FDR by setting the value of ∆ (the difference between
observed and expected values of d(g)) according to what the researcher considers
tolerable. In addition, the user must select a value for the permutations B, to compute
significance. Initially, this analysis was conducted with gene-averaged files with 20% of
the samples left out (see Table 5.1). The results of the model fitting step with B = 250,
indicated an unusually high FDR = ~0.74 for 162 genes, meaning that ~74% of the genes
were falsely declared significant.
We temporarily ignored the high FDR and built a k-NN prediction model, with k
= 5, to test each gene panel for three dichotomous survival rules (+/- 1yr, 2yr, 3yr).
Samples that were censored before the decision cut off were excluded from the LOOCV
estimator. For instance if the survival rule was +/- 1yr and a sample was censored at 280
days, it was excluded (Table 3.5). The gene panels (10, 20, 50 and 100 genes) were
nevertheless capable of producing LOOCV error rates ranging from 9 to 28 % depending
on the gene panel and survival rule. The classifier achieved its optimum ε = 0.09 (9%)
for k = 5 with the gene panel consisting of 100 genes and the survival rules for +/- 2 and
+/- 3 yrs. Earlier survival times were associated with higher values for ε but none were
above 28%. One-year survival was associated with 23-28% ε depending on the gene
panel. The two-year survival had a slightly broader range for ε (8 -20 %). Three-year
survival had a similar profile (ε =8-21%) to the 2yr rule. Error rates for all gene panels
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and classification rules are listed in Table 3.5. In general the 50 gene panel preformed the
best regardless of the decision rule, while the 10 gene panel preformed the worst.
The genes that resulted from this initial analysis were tested against the SMD data
set for their ability to predict a +/- 1year survival rule. It can be seen from Table 4.5 that
there was not good agreement between the two data sets with the 38 gene panel
predicting +/- 1yr survival with an ε of 47%
The survival analysis was then repeated with the decon files. For B = 250, an FDR
of 0.24 was achieved for 104 genes. These 104 genes are listed in appendix 7 and the
LOOCV results are listed in Table 3.6. The k-NN model was built with 100% of the
samples with the exception that censored observations were withheld if the censoring
occurred before the survival rule. For this analysis k = 7.
Generally, the error rates went up compared to the gene-averaged analysis, with
the lowest being 16% for the 3yr survival rule and the 50 gene panel. The 2yr survival
rule was associated with the lowest range of error rates and while the 1 and 3 yr rules
were associated with the lowest rate. For this analysis, the error rates were closer to the
error rates observed by applying common genes to prediction in the SMD data set. This
and the observed decrease in the FDR seems to indicate that this data is more accurate
than the gene-averaged data even though some of the same genes were called significant
in the survival analysis as in the decon analysis. Finally, the performance of a given gene
panel seemed to be affected by the survival rule such that a given gene panel did not
necessarily perform the same for all survival rules.
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Table 3.5. LOOCV error rates as a function of gene panel and survival rule.
LOOCV Error %

A

A

Sample Total

17/60 = 28

6/37= 16

11/23=48

23+37=60

20

13/6 = 22

5/37 = 13

8/23=35

50

14/60 = 23

5/37 =13

9/23=39

100

15/60 = 25

4/37= 10

11/23=48

12/60 = 20

5/31=16

7/29=24

20

11/60 = 18

4/31=13

7/29=24

50

12/60 = 20

5/31=16

7/29=24

100

5/60 = 8

1/31=3

4/29=14

12/56 = 21

4/31=13

7/23=30

20

9/56 = 16

3/33=9

6/23=26

50

8/56 = 14

2/33=6

6/23=26

100

5/56 = 8

1 /33=3

4 /23=17

16 / 19 = 84

8/11=73

8/8=100

7 of 20

12 / 19 = 63

5/11=45

7/8=88

17 of 50

15 / 19 = 78

7/11=64

8/8=100

38 of 100

9 / 19 = 47

4 /11=36

5 /8=63

Gene Panel

Survival

Class 1 Error %

Class 2 Error %

Rule

10

10

10

+/- 1yr

+/- 2yr

+/- 3yr

31+29 =60

33 +23 = 56

SMD Data

4 of 10

+/- 1yr

11 + 8 = 20

A

Class 1 error and class 2 error reflect the number of samples that were assigned to the

wrong class. For instance, for the 10 gene panel and +/- 1yr survival rule, 6 of the 37
samples that had less than 1 year survival were misclassified, while 11 of the 23
samples that had greater than 1 year survival were misclassified. This information
indicates whether one class is misclassified at a higer rate than the other class. The gene
panels for the SMD data were composed of only those genes that were in common
between the two array platforms (C3B and SMD).
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Table 3.6. LOOCV error rates as a function of gene panel and survival rule.
A

A

%

%

30/122 = 24

19/44=43

11/78=14

20

35/122= 28

21/44=47

14/78=18

50

40/122 =32

23/44=52

17/78=22

100

29/122 = 18

13/56=23

16/54=29

33/118 = 28

18/62=29

15/56=26

20

32/118 = 27

17/62=27

15/56=26

50

27/118 = 23

15/62=24

12/78=15

100

28/118 = 24

15/62=24

12/78=15

35/110 = 32

18/56=32

17/54=31

20

31/110 = 28

15/56=27

16/54=29

50

18/110 = 16

9/56=16

9 /54=17

100

29/110 = 26

13/56=23

16/54=29

9/19 = 47 (37)

5/11=45

4/8=50

5 of 20

13/19 = 68 (34)

7/11=63

6/8=75

19 of 50

8/19 =42 (38)

4/11=36

4/8=50

Gene Panel

Survival

LOOCV Error %

Rule

10

10

10

+/- 1yr

+/- 2yr

+/- 3yr

Class 1 Error

Class 2 Error

Sample Total

44+78=122

62+56 =118

56+54=110

SMD Data
2 of 10

+/- 1yr

11+8=19

A

Class 1 error and class 2 error reflect the number of samples that were assigned to the

wrong class. For instance, for the 10 gene panel and +/- 1yr survival rule, 6 of the 37
samples that had less than 1 year survival were misclassified, while 11 of the 23 samples
that had greater than 1 year survival were misclassified. This information indicates
whether one class is misclassified at a higer rate than the other class. The gene panels for
the SMD data were composed of only those genes that were in common between the two
array platforms (C3B and SMD).
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3.4 DISCUSSION
Unsupervised clustering revealed that the data derived from this set of
hybridizations do not generally form biologically meaningful clusters with out extensive
intensity and variance filtering. As a first step in data analysis, clustering can be used to
subjectively ascertain the level of noise present in the data. This analysis seems to
indicate that there is sufficient noise in the data as to mask the variation strictly due to
gene expression. This does not preclude the ability to use tests of significance to uncover
differential gene expression, however, it does indicate that low level regulation may be
difficult to identify with a high degree of certainty.
The analysis of malignancy grade indicated the data that we collected was not
especially capable of predicting class membership among most classes assayed. There
may be several reasons for this. It is known that histologically similar tumors (such as
GMs vs. AAs) are most likely to be histologically misclassified, and total-RNA samples
taken from these specimens may have been affected by this likelihood. Further, the AA
specimens are grade III malignancies and are highly likely to progress to GM tumors
even after treatment13,14,80 thus a large degree of biological similarity may also partially
account for our inability to find substantial differences in gene expression among these
tumors. The sample set we assayed was characterized by a large number of classes with a
relatively small number of specimens from each class. This too may have limited our
ability to detect stark difference among the tumors. Finally, it has been reported that the
Genisphere labeling technique is not as efficient at reproducing fold changes as other
labeling strategies (i.e., aminoallyl or dye conjugated nucleotides). However the fact that
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it is useful when sample amounts are limited (i.e., < 2 µg) dominated our decision when
selecting the labeling technique.
However, good feature selection and prediction results were achieved for the
comparison of GMs to OLs. This part of the analysis revealed 22 genes that were
significantly different between these two classes. Two genes identified, vimentin and

CD74, have been reported elsewhere to be important in distinguishing these two grades
of malignancy2, and because there is such a disparity in the survival between these
classes, these genes have been shown to be useful prognostic indicators. Further,

thymosin β10 has been implicated in anti-angiogenesis, tumor progression, and
neuroblastoma development105-107. This gene suppresses Ras function, which inhibits
angiogenesis and tumor growth108. In our study it was unregulated in OLs vs. GMs,
indicating that it may be a factor in the slow growing nature of OL neoplasms. These
results lend confidence in the accuracy of our findings with respect to classification of
GMs vs. OLs. Finally this analysis identified insulin-like growth factor binding protein 7
(IGFBP-7) as being a good distinguishing indicator of GMs and OLs. While many

IGFBPs have been implicated in glioma genetics, this is the first observation of IGFBP-7
as being a factor in diagnosis of the malignancy grade of gliomas.
Survival analysis of decon data revealed 104 genes significantly related to
survival with an FDR = 0.24. Genes that were common to the C3B and SMD platforms
showed marginal agreement with regard to the 1yr survival rule. This may be due to
several factors including small sample size, limited common genes between data sets and
gene panels, differences in platform performance, and large numbers of censored
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observations in our data set. Therefore follow up on these subjects may prove useful in a
subsequent analysis. The data was internally consistent, meaning that genes found in the
80% of tumors analyzed generalized well to the full 100% of samples we assayed.
However, it did not seem to be universally consistent, meaning that it did not predict 1yr
survival as well with the SMD data set.
The gene cysteine rich angiogenic inducer was identified to be significantly
related to survival and was generally over expressed in the GM specimens relative to the
lower grade malignancies particularly the PAs. This may indicate the increased level of
angiogenesis common to these tumors. This gene has been shown to be involved in
recurrence and metastasis in hepatocellular carcinomas109. The gene sarcoma amplified

sequence has been reported to be involved in growth and motility in osteosarcomas110
and was generally unregulated in the high grade tumors in our data.
Overall the findings of this study seem to have been limited by low sensitivity.
Several features of the analysis seemed to indicate this. Initial clustering based on the
majority of the genes failed to show significant clusters. Only after drastic reduction in
the number of genes were reasonable clusters obtained (Figure 3.4). Calculated FDRs for
most analyses were observed to be higher than expected.
Finally, class prediction error rates were also higher than initially expected. With
regard to the last point however, it has been noted elsewhere that classification error rates
are higher for brain tumor microarray data than for other neoplasms (i.e., lung, leukemia,
colon, and prostate)111, and it has been reported a 29.7% misclassification was observed
for brain tumor microarray data suggesting that our data, while it did not agree well with
the SMD data set, may not be that far off111. It may be that brain tumors represent a
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particularly challenging prediction problem and this may stem from the observed high
variability of gene expression in gliomas and GMs in particular.
Finally, from a gene expression point of view, the survival rules chosen may seem
arbitrary, but from a clinical standpoint they represent important knowledge on how
aggressive to be with treatment. For instance, if a histologically classified
oligodendroglioma patient has a gene expression profile that predicts less than one-year
survival than the clinician would be prudent to counsel a more aggressive therapy than
would be typical for this disease. In summary, the data presented did indicate several
interesting genes that may serve well as diagnostic and prognostic indicators. It also
demonstrated that care must be taken to avoid over optimism as even noisy data can be
internally consistent. It is therefore important to design experiments around several
corroborating techniques to demonstrate the accuracy of the findings.
3.4 FUTURE WORK
For the investigation described in chapter 3, there are several analyses that can be
conducted in the future to make more conclusive arguments with regard to survival. The
sensitivity for survival analysis may have been limited by the lack of covariates such as
patient age, prior health, or histological class in the model specification. A multivariate
Cox model may improve the FDR by accounting for covariates, such as age, that are
known to have significant prognostic value in patients with brain tumors. In our analysis,
all the PA tumors represented patients that were juvenile, and this particular grade of
malignancy is most likely to have a favorable prognosis. Detection of genes that are
significantly related to survival would also be improved by a larger sample size. In this
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case we ran only 50 (80%) tumors for survival analysis and this may have limited our
ability to detect genes related to survival. Even so, the SMD data were effectively
modeled without the presence of covariates in the model and achieved a low FDR (data
not presented) suggesting that this data was more robust to the effects of covariates.
For the prediction step, the error rates may be more accurately represented if use
was made of v-fold cross validation as opposed to leave-one-out cross validation. While
both types are known to be unbiased, the latter is associated with a higher variance and
thus may be over optimistic67,70. Together these suggestions may improve agreement of
our data to independent data sets.
Finally, it may be useful to run the same samples on Affymetrix (or other
commercial products) arrays to get an independent indication of the correlation among
C3B arrays. In addition, a completely independent set of samples could be assayed on
both platforms which would be helpful in determining how accurate the results are from
each single platform.
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APPENDIX 1
WHO Malignancy

Histological

Grade

Classification

Grade I

Pilocystic astrocytoma,

Grade II

Low grade astrocytoma

Grade III

Anaplastic astrocytoma

Grade IV

Glioblastoma Multiforme

Grade II

Oligodendroglioma

Grade III

Anaplastic

Histology

oligodendroglioma

Table A1. Astrocytoma grades and histological examples of each grade.
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APPENDIX 2
Table A2. Control genes added to the MWG 10k A Pan human oligo set
Accession Number

.

Control Genes

M33197

GAPDH 5’

M33197

GAPDH 3’

X00351

Beta Actin 5’

X00351

Beta Actin 3’

M97935

ISGF 5’

M97935

ISGF 3’

J04422

Bio B

J04423

Bio C

J04424

BioD

X04603

ThrC

M24537

Phe B

M64784

phosphofructokinase, platelet

M27396

asparagine synthetase

M11560

aldolase A, fructose-bisphosphate

XM_083842

phosphoglycerate mutase 1 (brain)

M12996

glucose-6-phosphate dehydrogenase

AB061838

ribosomal protein S3

XM_088688

non-POU-domain-containing, octamer-binding

NM_002954

ribosomal protein S27a

NM_005566

lactate dehydrogenase A

NM_000291

phosphoglycerate kinase 1

NM_014763

mitochondrial ribosomal protein L19

AA453756

Rho GDP dissociation inhibitor (GDI) alpha

NM_005566

lactate dehydrogenase A

NM_004048

beta-2-microglobulin

M64784

phosphofructokinase, platelet

M11560

aldolase A, fructose-bisphosphate

NM_002954

ribosomal protein S27a

G
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APPENDIX 3
Table A3. Brain tumor related genes added to the 10KO Table
1

NM_004341_1

carbamoylphosphate synthetase 2/aspartate transcarbamylase/dihydroorotase

2

X86098_1

BS69 protein

3

K01396_1

H alpha-1-antitrypsin mRNA. 11/1994"

4

NM_022111_1

claspin; CLSPN

5

X95735_1

zyxin.

6

BC010577_1

granulin, mRNA (cDNA clone MGC:9342 IMAGE:3457813)

7

U67963_1

lysophospholipase homolog (HU-K5)

8

J05243_1

nonerythroid alpha-spectrin (SPTAN1)

9

J02611_1

apolipoprotein D mRNA

10

J04599_1

hPGI mRNA encoding bone small proteoglycan I (biglycan)

11

M17783_1

glia-derived nexin (GDN) mRNA, 5' end. 4/1993"

12

U20498_1

p19 protein mRNA, complete cds. 1/1996"

13

NM_001878_1

cellular retinoic acid binding protein 2; CRABP2

14

M10905_1

cellular fibronectin mRNA. 11/1994

15

L07493_1

replication protein A 14kDa subunit (RPA)

16

NM_020349_1

ankyrin repeat domain 2; ANKRD2

17

NM_018659_1

cytokine-like 1; CYTL1

18

M34458_1

lamin B mRNA

19

M87339_1

replication factor C, 37-kDa subunit mRNA, complete cds. 10/1996"

20

X77584_1

ATL-derived factor/thiredoxin. 9/2004

21

M28215_1

GTP-binding protein (RAB5) mRNA, complete cds. 1/1995

22

D00632_1

glutathione peroxidase, complete cds. 3/1998

23

Z21507_1

EF-1delta gene encoding human elongation factor-1-delta. 1/1994

24

NM_052951_1

terminal deoxynucleotidyltransferase interacting factor 1; DNTTIP1

25

X74794_1

P1-Cdc21 mRNA. 9/1996

26

NM_001810_1

centromere protein B; CENPB

27

J04164_1

interferon-inducible protein 9-27 mRNA, complete cds. 4/1993"

28

X77588_1

TE2 mRNA for ARD-1 N-acetyltransferase homologue. 7/1994

29

X62534_1

HMG-2 mRNA. 11/1991

30

M61764_1

gamma-tubulin mRNA, complete cds. 11/1994

31

U51477_1

diacylglycerol kinase zeta mRNA, complete cds. 5/1996

32

M23178_1

homologue-1 of gene encoding alpha subunit of murine cytokine (MIP1/SCI),

33

NM_016382_1

CD244 natural killer cell receptor 2B4; CD244

34

L29222_1

clk1

35

U90551_1

histone 2A-like protein (H2A/l)
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APPENDIX 3 CONT.
Table A3. continued. Brain tumor related genes added to the 10KO
Accession #

Gene Name

36

NM_032493_1

adaptor-related protein complex 1, mu 1 subunit; AP1M1

37

U52828_1

delta-catenin mRNA,

38

U33632_1

two P-domain K+ channel TWIK-1

39

X53793_1

ADE2H1 mRNA showing homologies to SAICAR synthetase

40

X60486_1

H4/g gene for H4 histone.

41

NM_032545_1

cryptic; CFC1

42

NM_033259_1

CaM-KII inhibitory protein; CAM-KIIN

43

U52100_1

XMP

44

NM_004244_1

CD163 antigen isoform a; CD163

45

NM_001826_1

CDC28 protein kinase 1B; CKS1B

46

X51405_1

for carboxypeptidase E (EC 3.4.17.10). 3/1995

47

NM_001645_1

apolipoprotein C-I precursor; APOC1

48

AF010314_1

Pig10 (PIG10) mRNA, complete cds. 1/1998"

49

X97324_1

adipophilin. 3/1997

50

NM_138455_1

collagen triple helix repeat containing 1; CTHRC1

51

NM_001323_1

cystatin M precursor; CST6

52

U73379_1

cyclin-selective ubiquitin carrier protein mRNA

53

X69838_1

G9a.

54

X82434_1

emerin.

55

M36711_1

sequence-specific DNA-binding protein (AP-2) mRNA,

56

L14542_1

lectin-like type II integral membrane protein (NKG2-E) mRNA,

57

NM_052842_1

BCL2-like 12 isoform 2; BCL2L12

58

U07358_1

protein kinase (zpk) mRNA, complete cds. 5/1995

59

U21090_1

DNA polymerase delta small subunit mRNA, complete cds. 10/1995

60

D89667_1

mRNA for c-myc binding protein, complete cds. 2/1999"

61

U33267_1

glycine receptor beta subunit (GLRB) mRNA, complete cds. 12/1996

62

NM_130468_1

dermatan 4 sulfotransferase 1; D4ST1

63

X54942_1

ckshs2 mRNA for Cks1 protein homologue. 4/1992

64

NM_005209_1

crystallin, beta A2; CRYBA2"

65

M91670_1

ubiquitin carrier protein (E2-EPF) mRNA, complete cds. 12/1994

66

M55542_1

guanylate binding protein isoform I (GBP-2) mRNA, complete cds. 4/1993

67

M94345_1

macrophage capping protein mRNA, complete cds. 1/1995"

68

U46744_1

dystrobrevin-alpha mRNA, complete cds. 4/1996

69

U65932_1

extracellular matrix protein 1 (ECM1) mRNA, complete cds. 8/1996

70

U79299_1

neuronal olfactomedin-related ER localized protein mRNA

71

U28386_1

nuclear localization sequence receptor hSRP1alpha

72

NM_052999_1

chemokine-like factor superfamily 1 isoform 13; CKLFSF1

73

X16841_1

for a nontransmembrane isoform of N-CAM from skeletal muscle. 9/2004

74

X78565_1

for tenascin-C, 7560bp. 5/1995"

75

X66360_1

PCTAIRE-2 for serine/threonine protein kinase. 1/1993

76

L37936_1

nuclear-encoded mitochondrial elongation factor Ts (EF-Ts)

77

NM_080603_1

zinc finger, SWIM domain containing 1; ZSWIM1

78

U43885_1

Grb2-associated binder-1
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APPENDIX 4
Table A4. NQC data for arrays hybridized in the brain tumor study.
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APPENDIX 5
Table A5. Sample distrubution and survival times for brain tumors assayed.
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APPENDIX 6

Figure A6. Correlation averages for Alexafluor 647 (top) and Alexafluor 546
(bottom) channels for C3B arrays. Alexafluor 647 channel was the reference channel,
and the Alexafluor 546 channel was the sample channel. The x-axis represents
individual arrays and the y-axis represents calculated correlation averages for all pairwise array correlations. Error bars represent the standard deviation among the pairwise correlation calculations.
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APPENDIX 7
Table A7 Significant gene related to survival.
A

Gene

d0

Panel Gene

d0 Exptected Observed

NM_005981_1 sarcoma amplified sequence SAS

-0.023879

-3.242619

NM_004172_1 solute carrier family 1 glial high affinity glutamate transporter

0.8284317

-3.022238

NM_014699_1 KIAA0296 gene product KIAA0296

0.1773652

-2.924185

XM_071619_1 similar to Ser Arg related nuclear matrix protein plenty of prolines 101

0.5690327

-2.75241

NM_000582_1 secreted phosphoprotein 1

0.0380829

-2.734897

NM_004059_1 cysteine conjugate beta lyase

0.0224218

-2.656671

NM_001885_1 crystallin alpha B CRYAB

0.2697162

-2.490686

NM_022082_1 hypothetical protein FLJ23412 FLJ23412

-0.642498

-2.297341

NM_018299_1 hypothetical protein FLJ11011 FLJ11011

0.3351757

-2.27485

NM_002489_1 similar to NADH dehydrogenase ubiquinone 1 alpha subcomplex

-0.516387

-2.2423

NM_000773_1 cytochrome P450 subfamily IIE ethanol inducible CYP2E

0.0147565

-2.225285

XM_038988_1 basement membrane induced gene ICB 1

0.6088045

-2.221171

XM_011281_1 hypothetical protein PRO1580 PRO1580

0.0369406

-2.217762

NM_018340_1 similar to hypothetical protein FLJ11151

-0.523155

-2.214486

NM_021126_1 mercaptopyruvate sulfurtransferase MPST

-0.581941

-2.210816

NM_052842_1 BCL2-like 12 isoform 2; BCL2L12 1

1.8954514

-2.202491

BC014644_1 similar to high mobility group nonhistone chromosomal protein 17

-1.153229

-2.196156

NM_000272_1 nephronophthisis 1 juvenile NPHP1

0.4966613

-2.176307

NM_002433_1 myelin oligodendrocyte glycoprotein MOG

-0.241989

-2.156389

NM_053036_1 neuropeptide G protein coupled receptor neuropeptide

0.0450747

-2.154447

NM_003884_1 p300 CBP associated factor PCAF

0.0466943

-2.152312

NM_001586_1 chromosome X open reading frame 2 CXORF2

0.0877754

-2.134287

NM_016610_1 Toll like receptor 8 LOC51311

-0.644839

-2.13223

NM_020162_1 hypothetical protein DKFZp762F2011 DKFZp762F2011

0.1585426

-2.124117

NM_005166_1 amyloid beta A4 precursor like protein 1 APLP1

-0.145051

-2.108784
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NM_006574_1 chondroitin sulfate proteoglycan 5 neuroglycan C CSPG5

0.4493752

-2.10041

XM_017093_1 hypothetical protein FLJ23537 FLJ23537

1.2634244

-2.099067

NM_018351_1 hypothetical protein FLJ11183 FLJ11183

0.0017572

-2.066803

NM_016941_1 delta Drosophila like 3 DLL3

0.1262889

-2.063305

NM_004765_1 B cell CLL lymphoma 7C BCL7C

0.1735181

-2.055361

NM_001446_1 similar to fatty acid binding protein 7 brain

0.3582606

-2.049895

NM_006812_1 amplified in osteosarcoma OS 9

-0.020539

-2.048796

0.430469

-2.046858

NM_002519_1 similar to nuclear protein ataxia telangiectasia locus

-0.269328

-2.045158

NM_022783_1 hypothetical protein FLJ12428 FLJ12428

-0.341256

-2.043382

NM_001828_1 Charot Leyden crystal protein CLC

-0.560267

-2.042737

XM_007370_1 estrogen receptor 2 ER beta ESR2

-0.045282

-2.031634

NM_004808_1 N myristoyltransferase 2 NMT2

0.3063358

-2.022434

NM_019052_1 HCR a helix coiled coil rod homologue HCR

0.7611428

-2.002306

NM_003671_1 CDC14 cell division cycle 14 S cerevisiae homolog B

-0.242518

-2.002179

NM_016282_1 adenylate kinase 3 alpha like AKL3L

0.6670356

-1.978206

NM_004717_1 diacylglycerol kinase iota DGKI

0.0243335

-1.977256

1.488031

-1.961508

NM_025150_1 hypothetical protein FLJ12528 FLJ12528

-0.387669

-1.955981

NM_001683_1 ATPase Ca++ transporting plasma membrane 2 ATP2B2

-0.227049

-1.948935

NM_000533_1 proteolipid protein P

0.0752973

-1.936391

0.085064

-1.930121

NM_024700_1 hypothetical protein FLJ12553 FLJ12553

-0.360248

-1.92869

NM_002612_1 pyruvate dehydrogenase kinase isoenzyme 4 PDK4

0.3506014

-1.922289

-0.63335

-1.92225

XM_009122_1 selenoprotein W 1 SEPW1

1.5054079

-1.92169

NM_018962_1 Down syndrome critical region gene 6 DSCR6

0.0990775

-1.916915

0.123034

-1.90938

-0.096815

-1.904077

0.070982

-1.902981

NM_006454_1 Mad4 homolog MAD4

0.0414242

-1.888498

NM_002928_1 regulator of G protein signalling 16 RGS16

0.5035423

-1.87524

NM_024654_1 hypothetical protein FLJ23323 FLJ23323

-0.351743

-1.873864

NM_016185_1 hematological and neurological expressed 1 HN1

-0.428936

-1.869245

NM_000788_1 deoxycytidine kinase DCK

XM_071577_1 acid fibroblast growth factor like protein GLIO703

NM_013364_1 paraneoplastic cancer testis brain antigen MA5

NM_016376_1 ANKHZN protein ANKHZN

NM_004877_1 glia maturation factor gamma GMFG
NM_002734_1 protein kinase cAMP dependent regulatory type I
NM_017821_1 hypothetical protein FLJ20435 FLJ20435
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NM_006359_1 solute carrier family 9 sodium hydrogen exchanger isoform 6

-0.202375

-1.862702

NM_004738_1 VAMP vesicle associated membrane protein associated protein B and C

-0.143195

-1.859751

NM_000898_1 monoamine oxidase B MAOB

-0.183845

-1.848203

NM_006991_1 similar to ADP ribosylation factor like 4

-0.462676

-1.845542

NM_006770_1 macrophage receptor with collagenous structure MARCO

0.0468516

-1.843902

NM_016415_1 clone FLB3816 LOC51216

-0.898242

-1.814268

0.56164

-1.81148

NM_021927_1 hypothetical protein FLJ13220 FLJ13220

-0.224213

-1.807185

NM_024330_1 hypothetical protein MGC4365 MGC4365

-0.428338

-1.805333

NM_021784_1 hepatocyte nuclear factor 3 beta HNF3B

-0.654358

-1.802306

NM_000083_1 chloride channel 1 skeletal muscle

0.3619369

-1.801662

NM_017601_1 similar to hypothetical protein DKFZp761H221

-0.444022

-1.797454

-0.14302

-1.797368

NM_001648_1 kallikrein 3 prostate specific antigen KLK3

-1.001829

-1.793426

NM_005178_1 B cell CLL lymphoma 3 BCL3

-0.574258

-1.79341

NM_004268_1 cofactor required for Sp1 transcriptional activation

0.6405076

-1.786783

0.494296

-1.783971

NM_001672_1 agouti mouse signaling protein ASIP

0.1130363

-1.783246

NM_022552_1 DNA cytosine 5 methyltransferase 3 alpha DNMT3A

-0.383603

-1.779418

NM_004666_1 vanin 1 VNN1

0.3738589

-1.772467

BC009026_1 ligase III DNA ATP dependent LIG3

-0.599535

-1.771561

NM_001160_1 apoptotic protease activating factor APAF1

-0.573522

-1.765291

NM_025105_1 hypothetical protein FLJ12409 FLJ12409

-0.339748

-1.762865

NM_006716_1 hypothetical gene supported by NM_006716 LOC82512

-0.527153

-1.762787

NM_001902_1 similar to cystathionase cystathionine gamma lyase

0.5262126

-1.75797

NM_021098_1 similar to calcium channel voltage dependent alpha 1H subunit

-0.423837

2.079795

NM_006293_1 TYRO3 protein tyrosine kinase TYRO3

0.2080335

2.0850642

NM_004270_1 cofactor required for Sp1 transcriptional activation subunit 9 33kD

0.7962818

2.1021187

NM_000342_1 solute carrier family 4 anion exchanger member 1

0.1673858

2.1021528

NM_005688_1 ATP binding cassette sub family C CFTR MRP member 5

0.9328213

2.1118648

-0.31455

2.119763

NM_000852_1 glutathione S transferase pi GSTP1

0.2686803

2.1588387

NM_014588_1 visual system homeobox 1 zebrafish homolog CHX10 like

-0.296528

2.1772947

NM_018496_1 similar to hypothetical protein PRO0889

-1.230039

2.218164

XM_071571_1 similar to clone FLB3816 H sapiens LOC82147

NM_000744_1 cholinergic receptor nicotinic alpha polypeptide 4 CHRNA4

NM_000090_1 collagen type III alpha 1 E

NM_025134_1 hypothetical protein FLJ12178 FLJ12178
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NM_018358_1 hypothetical protein FLJ11198 FLJ11198

0.9563472

2.2672145

NM_022473_1 zinc finger protein 106 ZFP106

-0.747348

2.2685475

NM_005500_1 SUMO 1 activating enzyme subunit 1 SAE1

-0.580502

2.3193085

NM_004341_1 carbamoylphosphate synthetase 2

0.6151074

2.359525

-0.3233

2.3829834

NM_001554_1 cysteine rich angiogenic inducer 61 CYR61

0.5356279

2.452571

NM_017818_1 hypothetical protein FLJ20430 FLJ20430

0.5403622

2.5232244

NM_024663_1 hypothetical protein FLJ11583 FLJ11583

-0.323477

2.6286561

NM_006636_1 methylene tetrahydrofolate dehydrogenase NAD+ dependent

0.5007502

2.6340063

NM_004537_1 nucleosome assembly protein 1 like 1 NAP1L1

0.2572645

2.7493677

NM_025098_1 hypothetical protein FLJ22644 FLJ22644

A

Green rows were genes that made up the 10 gene panel, red the 20 gene panel, blue the

50 gene panel, and pink the 100 gene panel such that each increasing gene panel
contained genes from the reduced panels, for example, the 20 gene panel contained 10
green gene rows and 10 red gene rows. The white rows were excluded from the analysis.
Cells highlighted in grey are genes that were common betweent the C3B and SMD
arrays.

